Wyeth ˇ 8-K ˇ For 3/13/02 ˇ EX-13
Filed On 3/13/02 ˇ SEC File 1-01225 ˇ Accession Number 5187-2-3
As Of Filer Filing As/For/On Docs:Pgs
3/13/02 Wyeth 8-K{5,7} 3/13/02 2:71
Document/Exhibit Description Pages Size
1: 8-K Current Report 3 8K
2: EX-13 Annual or Quarterly Report to Security Holders 68 418K
EX-13 ˇ Annual or Quarterly Report to Security Holders
Exhibit Table of Contents
HIGHLIGHTS
Years Ended December 31,
(In thousands except per share amounts)
[Download Table]
2001 2000
Net Revenue $14,128,514 $13,213,671
Income from Continuing Operations
before Unusual Items* 2,900,294 2,514,004
Diluted Earnings per Share
before Unusual Items* 2.18 1.90
Income (Loss) from Continuing Operations 2,285,294 (901,040)
Diluted Earnings (Loss) per Share from
Continuing Operations 1.72 (0.69)
Dividends per Common Share 0.92 0.92
Total Assets 22,967,922 21,092,466
Stockholders' Equity 4,072,573 2,818,093
[Download Table]
Contents
Message to Stockholders 2
Strong Product Growth... for Today and Tomorrow 7
Wyeth's Pipeline for Growth 28
Principal Products 30
Financial Review 31
Directors and Officers 67
Corporate Data 68
Mission, Vision and Values IBC
*For identification of each specific unusual item occurring in 2001 and 2000,
refer to "2001, 2000 and 1999 Unusual Transactions" on page 60 within
Management's Discussion and Analysis of Financial Condition and Results of
Operations.
[PICTURE OF ROBERT ESSNER]
Robert Essner, President and Chief Executive Officer
MESSAGE TO STOCKHOLDERS
The change of our corporate name to Wyeth on March 11, 2002 clearly
signals the emergence of American Home Products Corporation (AHP) as a
top-tier global pharmaceutical company.
Our outstanding results in 2001 - the year in which AHP celebrated its
75th anniversary - reflect the strength of the Company and its products.
Worldwide net revenue increased by 7 percent to more than $14 billion, and
income from continuing operations - excluding unusual items detailed in
the financial section of this report - grew by 15 percent for the year, to
$2.9 billion, the highest operating earnings in our history.
To maintain that momentum, we are intensifying our focus on innovative
first- and best-in-class medicines while making major investments in
manufacturing and quality assurance across our global supply chain. Our
employees are united in a common mission with shared values that will
allow us to achieve an ambitious vision: to be recognized as the best
pharmaceutical company in the world.
We foresee robust, long-term growth for Wyeth because the Company has a
unique combination of strategic assets that set us apart from our
competitors:
- STRONG FOUNDATION PRODUCTS - Our current product portfolio includes the
PREMARIN family of hormone replacement therapy (HRT) products - which
became Wyeth's first $2 billion product line in 2001 - and EFFEXOR/EFFEXOR
XR, our novel antidepressant, which reached $1.5 billion in sales in 2001.
We also have some of the world's best-known consumer health care brands,
including ADVIL, CENTRUM and ROBITUSSIN.
- SUCCESSFUL NEW PRODUCTS - In the last three years, Wyeth has launched nine
new products, and three of these have been among the most successful
prescription medication launches of all time: ENBREL, PREVNAR and
PROTONIX. These three products together produced sales of more than $2.2
billion in 2001, and each has the potential to exceed $1 billion in annual
sales in the near future. Two important new products - FLUMIST, an
innovative intranasal influenza vaccine, and rhBMP-2, a locally applied
recombinant protein therapy that induces bone growth - are expected to
reach the market during 2002.
- FAVORABLE PATENT SITUATION - With the success of our new products, Wyeth
has one of the lowest exposures to near-term patent expiration of all the
major pharmaceutical companies, a tremendous competitive advantage. Our
broad-based portfolio also means that our growth is not dependent on the
success or patent life of one or two products.
2
- ROBUST PIPELINE - We have built an impressive new product pipeline across
a wide range of therapeutic areas that address significant unmet medical
needs. We expect this pipeline to yield several new first- or
best-in-class products by 2004-2005.
- UNIQUE R&D TECHNOLOGY BASE - Wyeth is one of a select few major
pharmaceutical companies with significant research programs, manufacturing
capabilities and marketed products in three discovery and development
platforms: small molecules, proteins and vaccines. We also are one of the
world's largest biotechnology companies. This breadth of expertise
provides unique research synergies and fuels our ability to explore
multiple paths in the search for new therapies.
All of these assets are driven by our most important resource: the talent,
commitment and experience of our more than 52,000 employees around the
world.
RESULTS OF OPERATIONS
Wyeth's worldwide net revenue for 2001 grew to $14.1 billion, an increase
of 7 percent over 2000 net revenue. Excluding the negative impact of
foreign exchange, worldwide net revenue increased by 9 percent for the
year. Income and diluted earnings per share from continuing operations -
including unusual items - were $2.3 billion and $1.72, respectively. This
compares with a loss and diluted loss per share from continuing operations
of $901 million and $0.69, respectively, in 2000.
The 2000 results included a $7.5 billion charge related to litigation
involving the diet drugs REDUX and PONDIMIN. In 2001, we took an
additional diet drug litigation charge of $950 million to cover additional
anticipated funding requirements for the nationwide, class action
settlement and other estimated costs associated with the litigation. On
January 3, 2002, as a result of the completion of the appeals process, the
class action settlement regarding the diet drugs received final judicial
approval.
Excluding these and other unusual items from the 2001 and 2000 results -
and including the dilutive effect of common stock equivalents in 2000 -
income and diluted
Income from continuing operations grew by 15 percent for the year.
[PICTURE OF JOHN R. STAFFORD]
John R. Stafford, Chairman of the Board
Pharmaceutical Net Revenue
($ in millions)
[PLOT POINTS TO COME]
3
earnings per share from continuing operations for 2001 increased by 15
percent to $2.9 billion and $2.18, respectively, compared with $2.5
billion and $1.90, respectively, in 2000.
In December 2001, Amgen Inc. and Immunex Corporation announced that Amgen
would acquire Immunex, a company in which Wyeth is the largest
shareholder. Wyeth and Immunex co-promote ENBREL - the breakthrough
treatment for rheumatoid arthritis - in North America. Wyeth supports the
acquisition and has agreed to vote its shares in favor of the transaction
because we believe it will benefit the future growth of ENBREL. Wyeth will
continue to co-promote ENBREL in North America, and we retain exclusive
international rights to the product.
WYETH PHARMACEUTICALS
Wyeth's prescription pharmaceutical business, now called Wyeth
Pharmaceuticals, enjoyed strong growth in 2001. Worldwide net revenue for
human pharmaceuticals increased by 10 percent for the year to $10.9
billion. Excluding the negative impact of foreign exchange, the increase
was 12 percent for the year.
Sales of the PREMARIN family of HRT products continued to grow, surpassing
$2 billion in worldwide sales in 2001, an increase of 11 percent for the
year. EFFEXOR/EFFEXOR XR reached $1.5 billion in worldwide sales for
2001 - a 33 percent increase over 2000 - with the addition of a new
indication in the United States for use in preventing the relapse and
recurrence of depression.
ENBREL achieved sales of $856 million - an increase of 24 percent over
2000. In January 2002, ENBREL received a new indication in the United
States for the treatment of psoriatic arthritis, making it the first
therapy approved for this painful condition. Wyeth also is investing more
than $1 billion to increase ENBREL production capacity for the global
market.
PREVNAR, Wyeth's vaccine for the prevention of invasive pneumococcal
disease, is the most successful vaccine ever launched. It has reached
nearly 95 percent of all eligible infants and toddlers in the United
States after less than two years on the market. Sales of PREVNAR, launched
in the first quarter of 2000, increased by 73 percent to $798 million.
Wyeth's proton pump inhibitor (PPI), PROTONIX - licensed from Byk Gulden
for marketing in the United States - more than tripled its 2000 U.S. sales
to $561 million for 2001. It is the only PPI approved in both oral and
intravenous formulations for gastroesophageal reflux disease in the U.S.
market.
Other prescription pharmaceutical products with strong growth in 2001
included CORDARONE I.V. (an anti-arrhythmic); ZOSYN/TAZOCIN (an injectable
antibiotic); ALTACE (an angiotensin-converting-enzyme inhibitor); and our
recombinant therapies for hemophilia A and B, REFACTO and BENEFIX,
respectively.
PREMARIN products exceeded $2 billion in global sales in 2001.
WYETH CONSUMER HEALTHCARE
Wyeth Consumer Healthcare - the new name of our non-prescription consumer
health care products division - recorded $2.4 billion in worldwide net
sales, a slight decrease versus 2000.
Research and Development Expenditures
($ in millions)
[PLOT POINTS TO COME]
4
ADVIL, CENTRUM, CALTRATE and CHAP STICK experienced growth for the year,
while sales of cough/cold/allergy products such as ROBITUSSIN and DIMETAPP
decreased.
The division's brands remain some of the strongest and best known in the
world: Nine of our consumer products rank number one or two in their
categories in the United States, and three of our global brands - ADVIL,
CENTRUM and ROBITUSSIN - are among the top 12 consumer health care brands
worldwide.
FORT DODGE ANIMAL HEALTH
The Fort Dodge Animal Health Division - whose name remains unchanged
because it is highly recognized in its field and closely associated with
its products - recorded worldwide net sales of $776 million, a decline of
2 percent for 2001. This was primarily due to a general weakening in
livestock markets globally and continuing concerns about foot-and-mouth
and mad cow diseases. However, Fort Dodge introduced an innovative canine
heartworm preventative in the United States in 2001 that rapidly achieved
robust sales. The new treatment, called PROHEART 6, provides six months of
protection from heartworm infection with a single injectable dose.
INVESTING IN THE FUTURE
Wyeth continues to make substantial investments to support the Company's
growth. Our research and development expenditures in 2001 totaled nearly
$1.9 billion, and we expect that amount to exceed $2 billion in 2002. In
addition, we are in the second year of a five-year capital investment
initiative to expand our biopharmaceutical manufacturing capabilities in
the United States, and we are building a new $1.5 billion
biopharmaceutical development and manufacturing facility near Dublin,
Ireland. We expect our total capital spending in the five-year period from
2001 through 2005 to reach $7 billion, the majority of which is for
increased production capacity - a clear indication of our confidence in
the future.
In 2002, we will invest more than $300 million to support our number one
operating objective - to make sure that our manufacturing and operations
maintain high quality standards. Prior to our entry into a consent decree
with the U.S. Food and Drug Administration - focusing on Wyeth's
compliance with current Good Manufacturing Practices - we began a
companywide initiative to address these issues. Our efforts include
strengthening sustainable compliance by taking a more focused and rigorous
approach to the creation and standardization of robust procedures and
systems across our global supply chain and distribution network. Quality
and sustainable compliance will continue to be the highest priorities for
Wyeth in the years ahead.
Our research and development expenditures in 2001 totaled nearly
$1.9 billion.
It is with great sadness that we note the passing of William F. Laporte,
Director Emeritus and former Chairman and President of American Home
Products, in September 2001. Mr. Laporte was a tireless leader who spent
his entire 63-year business career at AHP. He was instrumental in building
the Company into the global pharmaceutical leader it is today.
5
INSIDE WYETH
On May 1, 2001, Robert Essner, President of Wyeth, was elected Chief
Executive Officer of the Company. John R. Stafford remains Chairman of the
Board. In June 2001, Lawrence V. Stein was elected Senior Vice President
and Deputy General Counsel, and Jeffrey S. Sherman was elected Vice
President and Associate General Counsel. In February 2002, Ulf Wiinberg
was appointed President of Wyeth Consumer Healthcare, and in March 2002,
Mary Katherine Wold was elected Vice President - Taxes.
In addition, two corporate officers retired in the past 12 months: Thomas
G. Cavanagh, Vice President - Investor Relations, in March 2001, after
more than 31 years of service to the Company; and Thomas M. Nee, Vice
President - Taxes, after more than 15 years of service, in February 2002.
We thank these individuals for their valuable contributions.
A BRIGHT FUTURE
With the strategic assets that we have in place and the investments we are
making for the future, Wyeth's growth potential has never been better. We
remain confident that we will deliver strong results in 2002 and beyond.
Our product portfolio is the most robust it has ever been. In 1997, we had
a single billion-dollar franchise: PREMARIN. Just five years later, in
2002, we expect to have two $2 billion franchises - PREMARIN and EFFEXOR -
and two additional billion-dollar products, ENBREL and PREVNAR, which were
not even on the market in 1997. We have one of the lowest
patent-expiration exposures in the industry. In addition, we have
unmatched research and development capabilities across the spectrum of
small molecules, proteins and vaccines.
In the near future, Wyeth expects to be the largest vaccine company in the
world. We already are one of the largest global manufacturers of
biopharmaceutical products. Furthermore, with our broad and deep pipeline,
we expect to introduce new products in 2004 and 2005 that will keep Wyeth
in the lead as an innovator of first- or best-in-class medicines.
We have the right people and the right business strategies in place to
realize this enormous potential. By working toward a common mission and
operating according to our values, we will achieve Wyeth's vision to be
the world's best pharmaceutical company.
Given the events of 2001 that touched all of us, we want to thank our
employees for their continued dedication and commitment to the success of
the Company. We are particularly proud of the thousands of employees who
contributed their time, effort and money to help the victims, families and
rescue workers affected by the September 11 tragedy. It is the strength of
all of us, working together to move ahead, that will create a bright
future. As we work, we have the satisfaction of knowing that our efforts
are producing medicines that make a difference in the lives of people
around the world, every day.
Wyeth's vision is to be the world's best pharmaceutical company.
/s/ Robert Essner
Robert Essner, President and
Chief Executive Officer
/s/ John R. Stafford
John R. Stafford, Chairman
of the Board
March 11, 2002
6
STRONG PRODUCT GROWTH ...
FOR TODAY AND TOMORROW
Outstanding brands, exciting new products and a rich research pipeline will
drive Wyeth's growth.
[Photo]
7
Wyeth's product portfolio, with major brands such as PREMARIN, EFFEXOR XR,
PREVNAR, ENBREL, PROTONIX, ADVIL and CENTRUM, is improving the quality of life
for millions of people around the world. These foundation products are expected
to produce strong sales growth over the next few years. During 2002, we
anticipate that FLUMIST and rhBMP-2 will join our product lineup, with the
potential to benefit millions of additional patients.
Wyeth also has one of the broadest and deepest new product pipelines in the
pharmaceutical industry. Our scientists currently are exploring more than 60 new
therapies targeting significant medical conditions such as diabetes, breast
cancer, multiple sclerosis, HIV, Alzheimer's disease and schizophrenia. Equally
important, Wyeth's research and development efforts have the unique capability
to take multiple paths toward discovering novel therapies.
This combination of strong existing products, promising research projects and
wide-ranging scientific resources should continue to drive Wyeth's growth while
addressing some of the world's most important medical needs.
Photo Caption:
"I started taking PREMARIN after a hysterectomy, and it made an immediate
difference in getting me back to normal. Now, more than 15 years later, I
continue to lead an active life. I enjoy long-distance swimming, and I'm also a
dancer. There's nothing I want to do that I can't do, and I credit PREMARIN for
that."
Marianne Anthe
Philadelphia, Pennsylvania
Callout:
More than 11 million women used a PREMARIN product last year for menopausal
symptoms and osteoporosis.
PREMARIN: 60 YEARS AND GROWING
Sales of the PREMARIN family of products increased by 11 percent in 2001, and
PREMARIN became the first Wyeth brand to surpass $2 billion in annual sales. In
the United States alone, more than 11 million women used a PREMARIN product last
year for relief of menopausal symptoms and for osteoporosis prevention. The
continuing popularity of PREMARIN is particularly remarkable for a brand that
will celebrate 60 years on the market in 2002.
To maintain this impressive legacy, Wyeth continues to enhance its hormone
replacement therapy (HRT) franchise. We have filed regulatory submissions for
lower dose formulations of PREMARIN and PREMARIN/MPA for the relief of vasomotor
symptoms related to menopause, as well as for the prevention of postmenopausal
osteoporosis. We anticipate final regulatory approval for these low-dose
products by the end of 2002.
8
[Photo]
9
[Photo]
10
Additionally, in the second half of 2002, a New Drug Application (NDA) will be
filed for an HRT product that combines PREMARIN with trimegestone, a novel
progestin.
While HRT is well-accepted by women in the United States, with about 30 percent
to 35 percent of eligible women taking advantage of this therapy, the number of
women using HRT in other parts of the developed world ranges from 20 percent to
less than 5 percent. Wyeth is continuing its efforts to bring the benefits of
HRT to millions of additional women worldwide through educational programs, new
products and, in the case of Japan, local clinical trials.
EFFEXOR: TREATING A GLOBAL HEALTH PROBLEM
Since its launch in 1994, EFFEXOR has helped millions of patients transform the
despair of depression and generalized anxiety disorder (GAD) into the joy of
everyday living. According to the World Health Organization, major depressive
disorder affects an estimated 120 million people worldwide - making it the
world's fourth greatest public health problem.
Photo Caption:
"I was always worried, even about the smallest things. EFFEXOR XR has helped
reduce my anxiety so I can be `me' again. My family relationships have improved,
especially with my three boys. I'm more fun and productive, and I'm better able
to deal with the worries of being a parent. EFFEXOR XR has restored me to the
person I really am."
Elizabeth Duthie, with son Kevin
Oyster Bay, New York
Callout:
EFFEXOR XR helps transform the despair of depression into the joy of everyday
living.
In 2001, EFFEXOR and EFFEXOR XR reached $1.5 billion in annual worldwide sales -
an increase of 33 percent over 2000. Momentum for EFFEXOR continues to build
with the addition of new indications as well as its approval in dozens of
countries for depression and GAD. EFFEXOR XR was approved by the U.S. Food and
Drug Administration (FDA) in May 2001 for use in preventing the relapse and
recurrence of depression. Also in 2001, Wyeth filed a supplemental NDA in the
United States and Canada for the use of EFFEXOR XR in social anxiety disorder.
Approval for this indication is expected before the end of 2002. Phase III
clinical trials are under way to evaluate EFFEXOR XR for the treatment of panic
disorder and for depression and GAD in pediatrics.
EFFEXOR/EFFEXOR XR is expected to maintain its strong growth performance over
the next few years and is targeted to reach sales of $3 billion by the end of
2004.
11
PREVNAR: REDUCING CHILDHOOD ILLNESSES
PREVNAR is Wyeth's innovative 7-valent vaccine for the prevention of invasive
pneumococcal disease, a major source of serious childhood illness. It is the
most successful vaccine product ever launched, achieving cumulative sales of
almost $1 billion in its first 18 months on the market. Sales in 2001 totaled
nearly $800 million - up by 73 percent over 2000. More important, millions of
infants and children have been vaccinated with PREVNAR, with immunization
compliance rates reaching as high as 95 percent for all eligible infants and
toddlers in the United States.
Callout:
PREVNAR is preventing thousands of cases of serious pneumococcal disease in
infants and children.
Photo Caption:
As a mother, you want to do everything you can to make sure your baby is happy
and healthy. When Alexa's doctor recommended PREVNAR, I saw it as an essential
ingredient to ensure her continued well-being. Now I have the peace of mind of
knowing that my daughter is protected against many serious childhood illnesses."
Elva Gomez, and daughter Alexa
Mountain View, California
Post-marketing studies show that PREVNAR has reduced the incidence of invasive
pneumococcal disease caused by the seven serotypes contained in the vaccine by
87 percent in infants under one year of age. The widespread use of PREVNAR in
the United States has made a major impact in helping prevent an estimated 17,000
cases of invasive pneumococcal disease that occurred every year prior to the
introduction of the vaccine. These invasive diseases, which can be associated
with significant morbidity and mortality, include bacteremia, septicemia,
bacteremic pneumonia and meningitis. The vaccine also has been approved in more
than 45 other countries. Negotiations are under way in many of those countries
concerning immunization recommendations and reimbursements, and we expect
international use of the vaccine to grow significantly over the next few years.
The PREVNAR story is far from over. Wyeth has a vaccine in Phase III clinical
trials that combines a 9-valent version of the pneumococcal vaccine with
MENINGITEC - Wyeth's successful meningococcal Group C vaccine. Research also is
under way to study the use of a pneumococcal vaccine in high-risk adults and to
expand the vaccine to include serotypes that are more prevalent in the
developing world, where invasive pneumococcal disease kills an estimated 1.2
million young children annually.
12
[Photo]
13
[Photo]
14
ENBREL: A BREAKTHROUGH FOR RHEUMATOID ARTHRITIS
Since its introduction in 1998, ENBREL has been used by more than 100,000
patients to relieve the symptoms of moderate to severe rheumatoid arthritis
(RA), for inhibiting the progression of structural damage in the joints of early
stage RA patients and for treating juvenile RA. ENBREL achieved sales of $856
million in 2001, a 24 percent increase over 2000. Wyeth co-promotes ENBREL in
North America with Immunex Corporation and has exclusive international rights to
the product.
Photo Caption:
"I can remember times when I was hardly able to move because of my rheumatoid
arthritis. I was physically and mentally drained. After I started using ENBREL,
I felt like I had been reawakened. I began zipping around like a young man. Now
I'm able to accomplish so much that I was missing out on, like painting. I feel
terrific."
George Beach
Philadelphia, Pennsylvania
Callout:
ENBREL helps control pain, swelling and other RA symptoms, allowing patients to
lead active and productive lives.
It is estimated that more than 6 million people are afflicted with rheumatoid
arthritis worldwide. Additionally, 2 million people have a related condition
called psoriatic arthritis - a painful chronic inflammatory disease
characterized by both joint and skin manifestations. In January 2002, the FDA
approved ENBREL for the treatment of psoriatic arthritis - the first therapy
specifically approved to reduce the signs and symptoms of this condition. A
regulatory submission for psoriatic arthritis in Europe was filed in late 2001.
ENBREL currently is undergoing Phase II clinical trials in Europe as a treatment
for psoriasis. Additionally, in February 2002, ENBREL received European
Commission approval for the treatment of early RA.
To meet the growing demand for this breakthrough biopharmaceutical therapy,
Wyeth is investing more than $1 billion to increase production capacity at
facilities in the United States and Ireland. These investments ultimately will
create the capacity to support $4 billion in annual ENBREL sales. Commercial
production from the expanded U.S. facility, located in West Greenwich, Rhode
Island, should begin in the second half of 2002, which will substantially
increase the availability of ENBREL for new patients.
PROTONIX: GROWING RELIEF FOR GERD
PROTONIX, Wyeth's proton pump inhibitor for the treatment of gastroesophageal
reflux disease (GERD), continued its strong growth in 2001. Licensed from Byk
Gulden for marketing in the United States, PROTONIX
15
achieved sales of $561 million in just its second year on the U.S. market -
almost four times its 2000 sales. With FDA approval of PROTONIX I.V. in March
2001, it also is the first and only proton pump inhibitor to be approved in both
oral and intravenous formulations for GERD - a condition caused by the chronic
reflux, or backup, of stomach acid into the esophagus that can cause significant
tissue damage if left untreated.
Wyeth continued to extend the product's treatment profile with the approval of
PROTONIX tablets in June 2001 for the maintenance of healing erosive esophagitis
and the reduction in relapse rates of heartburn symptoms in patients with GERD.
In addition, PROTONIX I.V. received approval for the treatment of pathological
hypersecretion associated with Zollinger-Ellison Syndrome (ZES), which is
characterized by chronic peptic ulcers caused by an oversecretion of stomach
acid. Wyeth also submitted a supplemental NDA for PROTONIX tablets for treating
ZES and is researching pediatric applications for PROTONIX.
Photo caption:
"Since my doctor switched me to PROTONIX, I don't have the lingering acidity
problems I had with other medications. In fact, I don't really think about my
condition anymore. That's a big difference for me. I enjoy cooking, and now I
don't have to adjust or eliminate seasonings in my favorite dishes. I can eat
whatever I like."
William Abrams
Maple Shade, New Jersey
Callout:
PROTONIX provides effective relief for gastroesophageal reflux disease.
OTHER GROWING PRODUCTS
While PREMARIN, EFFEXOR, PREVNAR, ENBREL and PROTONIX were major drivers of
growth for Wyeth's prescription pharmaceutical business in 2001, a number of
other products achieved significant results during the year, including:
- CORDARONE I.V., an antiarrhythmic medication, continued to experience steady
growth following the presentation of a major study demonstrating its superiority
for treating life-threatening arrhythmias. CORDARONE I.V. sales increased 31
percent in 2001, to $244 million.
- ZOSYN/TAZOCIN, a broad spectrum injectable antibiotic that is effective
against serious infections, attained $427 million in sales - an 11 percent
increase over 2000 - and now is available in 85 countries.
- ALTACE, an angiotensin-converting-enzyme (ACE) inhibitor co-promoted in the
United States by Wyeth and King Pharmaceuticals, Inc., experienced a 65 percent
increase in new prescriptions. ALTACE is the only ACE inhibitor with an
indication to reduce the risk of stroke, heart attack and cardiovascular death
in at-risk patients over age 55.
16
[Photo]
17
[Photo]
18
- REFACTO and BENEFIX, Wyeth's recombinant hemophilia treatments, reached
combined global sales of $360 million in 2001. REFACTO AF, an enhanced version
of the product made without the use of animal- or human-derived proteins in any
part of the manufacturing process, began Phase III clinical trials in 2001.
- RAPAMUNE, our novel immunosuppressant for kidney transplantation, more than
doubled its 2000 sales and was launched in 17 additional countries in 2001. More
than 7,000 transplant patients have used RAPAMUNE since its launch, and it now
is used by more than 100 major U.S. transplant centers that account for 75
percent of all transplants in the country.
GROWING FOR THE FUTURE
While the strength of Wyeth's existing product portfolio is providing
outstanding growth for the Company, our wide array of research programs holds
the potential to dramatically accelerate our future growth. Included among the
many projects in our development track are therapies that, if successful, could
revolutionize the treatment of serious medical conditions.
Photo Caption:
"I wrote my Ph.D. thesis on the evolution and mutation of the influenza virus
so it's a thrill for me to be working on the FLUMIST vaccine - knowing that it
should soon be available to help prevent this serious illness in adults and
children."
Debbie Buonagurio, Ph.D., Principal Research Scientist, Wyeth Research, shown in
the lab examining virus plaques, and in a field engaged in her favorite hobby,
bird watching.
Callout:
Wyeth scientists are exploring vaccine therapies for serious bacterial and viral
diseases.
DISCOVERING NEW VACCINES
The next exciting Wyeth product that we anticipate will reach the market is
FLUMIST, an innovative influenza vaccine licensed from Aviron. FLUMIST is unique
because it is administered as an easy-to-use nasal spray. An application for
regulatory approval in the United States was filed late in 2000, and FDA
approval is anticipated this year - in time for FLUMIST to be available for the
2002-2003 flu season.
Annual influenza outbreaks in the United States typically affect 10 percent to
20 percent of the general population and cause an estimated 20,000 deaths. The
efficacy of FLUMIST in children, combined with its easy-to-administer
formulation, could have a substantial impact on these outbreaks.
Wyeth also is applying its extensive experience in vaccine science to a variety
of other bacterial and viral diseases.
19
Phase I trials are being conducted for a combination vaccine against respiratory
syncytial virus and parainfluenza - two serious respiratory illnesses - and for
a herpes simplex vaccine. In addition, research is under way on
therapeutic/prophylactic vaccines for HIV.
IMPROVING WOMEN'S HEALTH
Wyeth's global leadership in women's health research continues to focus on
advances in hormone replacement therapy that could benefit millions of women
around the world. A major research effort is under way at Wyeth's Women's Health
Research Institute to develop new therapies that utilize tissue-selective
estrogens. These estrogens target receptors in specific tissue systems, such as
bone, offering the opportunity to optimize the efficacy and tolerability of
hormone therapies and to create a new treatment paradigm for postmenopausal
women.
In June 2001, Wyeth began Phase III clinical trials for bazedoxifene - a novel
tissue-selective estrogen receptor modulator - for the prevention and treatment
of postmenopausal osteoporosis. Phase III trials also have begun for a
menopausal therapeutic that combines bazedoxifene and PREMARIN.
Photo Caption:
"Our research in tissue-selective estrogens such as bazedoxifene could lead to a
new generation of hormone replacement therapies for postmenopausal women. I
enjoy the challenge of moving a new therapy through the clinical process and
proving that it works."
Barry Komm, Ph.D., Director, Cell Biology, Wyeth Research, pictured here
pursuing his passion for woodworking, with son Mickey, and working at a DNA
extractor in the lab.
Callout:
Women's Health researchers at Wyeth are focusing on advances that could benefit
millions of patients worldwide.
REPAIRING BONE
Another Wyeth innovation anticipated to reach the market in 2002 is rhBMP-2, a
recombinant protein therapy - locally applied - that induces bone growth. Wyeth
has filed for regulatory approval for rhBMP-2 in the United States and Europe as
a treatment for long-bone fractures that require surgical management. In January
2002, the Orthopedic and Rehabilitation Devices Panel of the FDA recommended
approval of an application from Medtronic Sofamor Danek, in collaboration with
Wyeth, for the use of rhBMP-2 in spinal fusion surgery. This indication is for
improvements in the surgical treatment of certain types of spinal degenerative
disc diseases. The surgery uses rhBMP-2 in combination with a medical device to
fuse vertebrae for the relief of lower back pain. This new procedure eliminates
the need for - and the pain of - harvesting bone from the hip for spinal fusion
surgery by using a collagen sponge
20
[Photo]
21
[Photo]
22
infused with rhBMP-2 to stimulate bone growth
and fuse the vertebrae. Phase III clinical trials also are under way to test
rhBMP-2 for dental/craniofacial surgical repair, and we expect to file an NDA
for this application by the end of 2002.
BATTLING CANCER
CCI-779 is one of several potential therapies in Wyeth's oncology product
pipeline designed to interfere with "signal transduction" - cellular processes
that "tell" a cell when to divide. By inhibiting the signals for cell division,
these compounds hold the potential to control tumor growth. CCI-779 is in Phase
II clinical trials for the treatment of patients with breast cancer. Phase III
trials for the treatment of renal cell carcinoma already are under way, and the
FDA has designated the compound for "fast-track" development in this indication.
In July 2001, Wyeth announced an agreement to collaborate with Taxolog, Inc. to
develop anti-tumor agents based on Taxolog's research into a class of compounds
that appear to block cell division by disrupting essential intracellular
mechanisms. In preclinical testing, the first of these compounds - MAC-321 -
demonstrated outstanding activity in recognized animal models of human cancer.
Photo Caption:
"Having spent years as an endocrinologist treating patients with type II
diabetes, I know that current therapies often have only limited effectiveness.
I'm excited about the potential of ertiprotafib to help the millions of people
affected by this life-threatening disease."
Kelly Davis, M.D., Assistant Vice President, Clinical R&D, Wyeth Research,
displaying her prized collection of majolica pottery, and giving a presentation
on ertiprotafib.
Callout:
Researchers in metabolic disorders at Wyeth are developing a potentially
life-saving diabetes treatment.
FIGHTING DIABETES AND HEART DISEASE
Non-insulin dependent diabetes mellitus (known as type II diabetes) affects
millions of people worldwide, and more than 700,000 patients with the condition
are diagnosed each year in the United States. In type II diabetes, tissues that
normally react to insulin develop a "resistance" to its actions, allowing blood
sugar levels to rise and altering vital processes in the body that can lead to
kidney failure, nerve damage and blindness.
Wyeth's metabolic disease researchers are developing a potentially life-saving
treatment for type II diabetes called ertiprotafib (PTP-112) - a small molecule
with a novel therapeutic action that keeps the insulin receptors "turned on" and
prolongs the body's responses to insulin. Ertiprotafib began Phase II clinical
trials in both the United States and Europe in 2001.
23
Wyeth's biotechnology resources also have created a recombinant protein therapy
called rPSGL-Ig that is in Phase II clinical trials to evaluate its ability to
accelerate clot destruction and prevent reperfusion injury following a heart
attack.
TARGETING ALZHEIMER'S DISEASE
One of Wyeth's most intriguing research efforts is targeted at Alzheimer's
disease - a devastating condition that affects millions of older adults around
the world and for which there is no current therapy that alters the onset or
progression of the disease. Wyeth's Neuroscience group is taking a multi-pronged
approach that draws on the Company's resources in all three technology platforms
to tackle this difficult disease.
One line of attack, being developed in conjunction with Elan Corporation,
involves several types of immunotherapies that are designed to reduce and
prevent the deposition of amyloid plaque in the brain - a substance believed to
be associated with the progression of Alzheimer's disease. Although the first of
these projects has been discontinued, other immunotherapeutics are in
preclinical development. In addition, Wyeth is developing a small molecule
therapy, SRA-333, that takes a completely different approach to the symptomatic
treatment of Alzheimer's disease. This experimental therapy is expected to begin
clinical trials before the end of this year.
Wyeth's Neuroscience group has several other promising therapies in development,
including a treatment for schizophrenia that is in Phase I trials and a therapy
for multiple sclerosis.
Photo Caption:
"As a fitness professional, I encounter people every day who get discouraged
about exercising because of soreness. Even after a lifetime of sports and
fitness, I still get sore muscles. I advise people to start a new exercise
program slowly, then build intensity and endurance. And I tell them that nothing
beats ADVIL to relieve muscle aches and get them back in the game."
Denise Austin
Washington, D.C.
Callout:
ADVIL is one of the world's top consumer health care brands.
BUILDING STRONG CONSUMER HEALTH BRANDS
Wyeth Consumer Healthcare continues to focus on building strong global brands.
Three of our well-established product lines - ADVIL, CENTRUM and ROBITUSSIN -
are among the top 12 consumer health care product franchises in the world. Other
key Wyeth Consumer Healthcare global brands include the CALTRATE family of
calcium supplements, CHAP STICK and
24
[Photo]
25
PREPARATION H. After more than 100 years on the market, CHAP STICK product sales
grew by 13 percent in the United States last year. U.S. sales of PREPARATION H -
a product that has been available for almost 50 years - increased by 16 percent
over 2000. The ADVIL Cold & Sinus family and CENTRUM PERFORMANCE, a premium
multivitamin, also showed strong growth in the United States.
New products or line extensions launched during 2001 include two new ROBITUSSIN
Syrup formulations, ROBITUSSIN Sunny Orange cough drops, PREPARATION H Wipes and
Children's ADVIL Blue Raspberry.
Callout:
PROHEART 6 provides six months of continuous protection from canine heartworm
infection with a single dose.
Caption:
"PROHEART 6 offers many advantages over traditional oral canine heartworm
treatments. It is administered intravenously in a veterinarian's office, so
PROHEART 6 eliminates concerns about owner compliance and whether a dosage was
really absorbed or rejected by the animal. And we have an accurate record of
exactly when each treatment was given."
Tim Haevernick, D.V.M.
Veterinarian
Mill Valley, California
BREAKTHROUGHS IN ANIMAL HEALTH
The highlight of 2001 for Wyeth's Fort Dodge Animal Health Division was the
approval and launch in the United States of PROHEART 6 - an innovative canine
heartworm preventative that is a breakthrough in animal health pharmaceuticals.
Unlike traditional heartworm preventatives, PROHEART 6 provides six months of
continuous protection from heartworm infection with a single injectable dose.
PROHEART 6 achieved global sales of $84 million in 2001. A similar product has
been approved in Australia, Japan and Italy.
Fort Dodge received a conditional license in the United States to distribute its
first-in-class West Nile Virus vaccine for horses to protect against this
sometimes fatal disease that has spread to more than 20 states. In Spain,
BIODECTIN, which provides immunization against clostridial diseases and
persistent treatment of parasites in sheep, was the first combination
pharmaceutical and biological product ever registered in Europe.
26
[Photo]
27
WYETH'S PIPELINE FOR GROWTH
Shown here are some of the new products and new indications which are in
post-Phase I clinical trials or have been submitted for regulatory approval.
[Enlarge/Download Table]
PHASE II PHASE III REGULATORY
REVIEW
Phase II: Phase III: Regulatory Review:
Determination Determination Evaluation of
of safe and of overall safety and
effective benefit/risk efficacy data
dosage for an ratio for an by governmental
experimental experimental regulatory
medicine, medicine, agencies
generally generally
conducted in conducted in
hundreds of thousands of
patients patients
WOMEN'S HEALTH CARE
BAZEDOXIFENE (TSE-424) Postmenopausal osteoporosis X X
BAZEDOXIFENE/PREMARIN(R) Postmenopausal osteoporosis X X
Vasomotor symptoms of menopause X X
PREMARIN(R) LOW DOSE Postmenopausal osteoporosis X X X
Vasomotor symptoms of menopause X X X
PREMARIN(R)/MPA LOW DOSE Postmenopausal osteoporosis X X X
Vasomotor symptoms of menopause X X X
PREMARIN(R)/TRIMEGESTONE Postmenopausal osteoporosis X X
Vasomotor symptoms of menopause X X
TRIMEGESTONE/17(BETA)-ESTRADIOL Postmenopausal osteoporosis (EU) X X
Vasomotor symptoms of menopause (EU) X X X
NEUROSCIENCE THERAPY
EFFEXOR(R) XR Depression and generalized anxiety disorder in pediatrics X X
Panic disorder X X
Social anxiety disorder (U.S. and Canada) X X X
VACCINES AND INFECTIOUS DISEASES
COLD-ADAPTED INFLUENZA VACCINE Liquid formulation X X
FLUMIST(TM) INTRANASAL INFLUENZA VACCINE Frozen formulation X X X
PREVNAR(R) Otitis media X X X
ZOSYN(R) Nosocomial pneumonia q6h (U.S.) X X
9-VALENT PNEUMOCOCCAL AND MENINGOCOCCAL GROUP C CONJUGATE VACCINE X X
28
[Enlarge/Download Table]
PHASE II PHASE III REGULATORY
REVIEW
MUSCULOSKELETAL THERAPIES
ENBREL(R) Ankylosing spondylitis X X
Psoriatic arthritis (EU) X X X
Psoriasis X
J695 (ANTI-IL-12) Rheumatoid arthritis (joint with Abbott Laboratories) X
rhBMP-2 Dental/craniofacial X X
Lumbar interbody spinal fusion (collaboration with Medtronic Sofamor Danek) X X X
Lumbar posterolateral spinal fusion (collaboration with Medtronic Sofamor Danek) X X
Orthopedic trauma (long-bone fractures requiring surgery) X X X
INTERNAL MEDICINE
CORDARONE(R) AQ (AMIODARONE AQUEOUS) Recurrent ventricular fibrillation and unstable
ventricular tachycardia (U.S.) X X
ERTIPROTAFIB (PTP-112) Type II diabetes X
PROTONIX(R) ORAL Zollinger-Ellison Syndrome (U.S.) X X X
rhIL-11 Oral therapy in inflammatory bowel disease X
rPSGL-Ig Acute coronary syndrome/acute myocardial infarction X
IMMUNOLOGY AND ONCOLOGY
CCI-779 Renal cell carcinoma X X
Various solid tumors X
MYLOTARG(R) Induction/consolidation in acute myeloid leukemia X
RAPAMUNE(R) Conversion in liver transplant X X
Conversion in renal transplant X X
Maintenance regimen in renal transplant (U.S.) X X X
Pediatric usage X X
HEMOPHILIA
REFACTO(R) AF Hemophilia A X X
29
PRINCIPAL PRODUCTS
WYETH
PHARMACEUTICALS
HEMOPHILIA
BeneFIX
ReFacto
IMMUNOLOGY & ONCOLOGY
Mylotarg
Neumega
Rapamune
INFECTIOUS DISEASES
Minocin
Minomycin
Pipracil
Suprax
Tazocin
Zosyn
INTERNAL MEDICINE
Altace (1)
Cordarone I.V.
Protonix
Protonix I.V.
Zebeta
Ziac
Zoton
MUSCULOSKELETAL
Enbrel (2)
Seltouch
Synvisc
NEUROSCIENCE
Efexor
Effexor
Effexor XR
Sonata
NUTRITIONALS
Materna
Nursoy
Progress
Progress Gold
Promil
Promil Gold
Promise
SMA
SMA Gold
S-26
S-26 Gold
VACCINES
FluShield
HibTITER
Meningitec
Pnu-Imune 23
Prevenar
Prevnar
WOMEN'S HEALTH CARE
Alesse
Harmonet
Loette
Lo/Ovral
Minesse
Minulet
Premarin
Premphase
Prempro
Totelle
Tri-Minulet
Trinordiol
Triphasil
WYETH
CONSUMER
HEALTHCARE
ANALGESICS
Advil
Anacin
Anadin
Children's Advil
Robaxin
Spalt
COUGH/COLD/ALLERGY
Advil Cold & Sinus
Dimetapp
Dristan
Robitussin
Robitussin Honey Products
NUTRITIONAL SUPPLEMENTS
Caltrate
Centrum
Centrum Jr.
Centrum Kids
Centrum Performance
Centrum Select
Centrum Silver
Polase
Solgar
Vitasprint B12
OTHER PRODUCTS
Anbesol
Chap Stick
FiberCon
Preparation H
Primatene
FORT DODGE
ANIMAL HEALTH
Biodectin
Bursine
Cydectin
Duramune
Duvaxyn
EtoGesic
Fel-O-Vax
Fluvac
LymeVax
Pentofel
Polyflex
Poulvac
ProHeart
Pyramid
Quest
Suvaxyn
ToDAY
ToMORROW
Torbugesic
Triangle
West Nile Virus Vaccine
(1) Co-promoted with King Pharmaceuticals, Inc.
(2) Co-promoted with Immunex Corporation
The above principal products are identified as trademarks used by Wyeth and its
subsidiaries.
30
FINANCIAL
REVIEW
Jerauld Skotnicki, Ph.D., Director, Discovery Chemical Sciences, Wyeth Research,
demonstrates the structure of the CCI-779 molecule.
[Download Table]
Ten-Year Selected Financial Data 32
Consolidated Balance Sheets 34
Consolidated Statements of Operations 35
Consolidated Statements of Changes
in Stockholders' Equity 36
Consolidated Statements of Cash Flows 37
Notes to Consolidated Financial Statements 38
Report of Independent Public Accountants 55
Management Report on Financial Statements 55
Quarterly Financial Data (Unaudited) 56
Market Prices of Common Stock and Dividends 56
Management's Discussion and Analysis of
Financial Condition and Results of Operations 57
[BACKGROUND PICTURE OF JERAULD SKOTNICKI, Ph.D.]
31
TEN-YEAR SELECTED FINANCIAL DATA
(Dollar amounts in thousands except per share amounts)
[Enlarge/Download Table]
YEARS ENDED DECEMBER 31, 2001 2000 1999
------------------------------------------------------------------------------------------------------------------------------
SUMMARY OF NET REVENUE AND EARNINGS
Net revenue(1)(2) $ 14,128,514 $ 13,213,671 $ 11,815,138
Income (loss) from continuing operations(1)(3) 2,285,294 (901,040) (1,207,243)
Diluted earnings (loss) per share from continuing operations(1)(3)(4) 1.72 (0.69) (0.92)
Dividends per common share 0.9200 0.9200 0.9050
YEAR-END FINANCIAL POSITION
Current assets(1) $ 9,766,753 $ 10,180,811 $ 12,384,778
Current liabilities(1)(5) 7,257,181 9,742,059 6,480,383
Ratio of current assets to current liabilities(1)(5) 1.35 1.05 1.91
Total assets(1) 22,967,922 21,092,466 23,123,756
Long-term debt(1)(6) 7,357,277 2,394,790 3,606,423
Average stockholders' equity(5) 3,445,333 4,516,420 7,914,772
STOCKHOLDERS -- OUTSTANDING SHARES
Number of common stockholders 64,698 58,355 62,482
Weighted average common shares outstanding used for
diluted earnings per share calculation (in thousands)(4) 1,330,809 1,306,474 1,308,876
EMPLOYMENT DATA(1)
Number of employees at year end 52,289 48,036 46,815
Wages and salaries $ 2,536,220 $ 2,264,258 $ 2,032,431
Benefits (including social security taxes) 691,018 602,816 593,222
32 Wyeth and Subsidiaries
TEN-YEAR SELECTED FINANCIAL DATA (CONTINUED)
[Enlarge/Download Table]
YEARS ENDED DECEMBER 31, 1998 1997 1996
---------------------------------------------------------------------------------------------------------------------------------
SUMMARY OF NET REVENUE AND EARNINGS
Net revenue(1)(2) $ 11,219,752 $ 12,027,541 $ 12,040,836
Income (loss) from continuing operations(1)(3) 2,152,344 1,747,638 1,651,617
Diluted earnings (loss) per share from continuing operations(1)(3)(4) 1.61 1.33 1.28
Dividends per common share 0.8700 0.8300 0.7825
YEAR-END FINANCIAL POSITION
Current assets(1) $ 10,698,188 $ 10,025,512 $ 10,310,256
Current liabilities(1)(5) 3,478,119 3,476,322 3,584,256
Ratio of current assets to current liabilities(1)(5) 3.08 2.88 2.88
Total assets(1) 20,224,231 19,851,517 19,924,666
Long-term debt(1)(6) 3,839,402 5,007,610 6,010,297
Average stockholders' equity(5) 8,895,024 7,568,672 6,252,545
STOCKHOLDERS -- OUTSTANDING SHARES
Number of common stockholders 65,124 64,313 67,545
Weighted average common shares outstanding used for
diluted earnings per share calculation (in thousands)(4) 1,336,641 1,312,975 1,287,790
EMPLOYMENT DATA(1)
Number of employees at year end 47,446 54,921 54,194
Wages and salaries $ 2,175,517 $ 2,428,518 $ 2,439,604
Benefits (including social security taxes) 577,930 619,528 614,179
[Enlarge/Download Table]
YEARS ENDED DECEMBER 31, 1995 1994(7) 1993 1992
---------------------------------------------------------------------------------------------------------------------------------
SUMMARY OF NET REVENUE AND EARNINGS
Net revenue(1)(2) $ 11,391,497 $ 8,828,732 $ 8,261,276 $ 7,819,957
Income (loss) from continuing operations(1)(3) 1,472,525 1,525,517 1,469,300 1,460,842
Diluted earnings (loss) per share from continuing
operations(1)(3)(4) 1.18 1.24 1.17 1.15
Dividends per common share 0.7550 0.7350 0.7150 0.6650
YEAR-END FINANCIAL POSITION
Current assets(1) $ 11,084,841 $ 11,321,682 $ 4,807,684 $ 4,552,077
Current liabilities(1)(5) 3,929,940 4,291,452 1,584,411 1,492,717
Ratio of current assets to current liabilities(1)(5) 2.82 2.64 3.03 3.05
Total assets(1) 20,721,093 21,328,267 7,687,353 7,141,405
Long-term debt(1)(6) 7,806,717 9,972,444 859,278 601,934
Average stockholders' equity(5) 4,898,550 4,065,295 3,719,539 3,431,568
STOCKHOLDERS -- OUTSTANDING SHARES
Number of common stockholders 68,763 71,223 72,664 73,064
Weighted average common shares outstanding used for
diluted earnings per share calculation
(in thousands)(4) 1,250,902 1,234,100 1,252,990 1,267,240
EMPLOYMENT DATA(1)
Number of employees at year end 58,957 70,300 51,399 50,653
Wages and salaries $ 2,512,418 $ 1,811,402 $ 1,654,984 $ 1,575,615
Benefits (including social security taxes) 641,169 439,572 396,045 367,899
----------
(1) As a result of the sale of the Cyanamid Agricultural Products business on
June 30, 2000, amounts for the years 1994 through 1999 were restated to
reflect this business as a discontinued operation. Beginning in 1994,
current assets include the net assets of the discontinued business held for
sale related to the Cyanamid Agricultural Products business.
(2) The Company early adopted new authoritative accounting guidance as of
January 1, 2001 reflecting certain rebates and sales incentives (i.e.,
coupons and other rebate programs) as reductions of revenues instead of
selling and marketing expenses. Net revenue for all prior periods presented
has been reclassified to comply with the income statement classification
requirements of the new guidance.
(3) See Management's Discussion and Analysis of Financial Condition and Results
of Operations for amounts related to gain on sale of Immunex common stock,
termination fee, litigation charges, goodwill impairment and special
charges for the years ended December 31, 2001, 2000 and 1999.
(4) The weighted average common shares outstanding for diluted loss per share
for 2000 and 1999 did not include common stock equivalents, as the effect
would have been antidilutive.
(5) As a result of the litigation charges of $7,500,000 and $4,750,000 in 2000
and 1999, respectively, related to the litigation brought against the
Company regarding the use of the diet drugs REDUX or PONDIMIN, current
liabilities have increased substantially in 2000 and 1999 compared with
prior years, and the ratio of current assets to current liabilities and
average stockholders' equity has decreased substantially in 2000 and 1999
compared with prior years.
(6) In the 2001 first quarter, the Company obtained a new $3,000,000 credit
facility to support increased commercial paper borrowings and issued
$3,000,000 of Senior Notes. The proceeds from these borrowings are used for
the Company's general corporate and working capital requirements, including
payments related to the REDUX and PONDIMIN diet drug litigation.
(7) The 1994 information reflects the acquisition of American Cyanamid Company
for the one-month period ended December 31, 1994.
Wyeth and Subsidiaries 33
CONSOLIDATED BALANCE SHEETS
(In thousands except share and per share amounts)
[Enlarge/Download Table]
DECEMBER 31, 2001 2000
----------------------------------------------------------------------------------------------------------------------------
ASSETS
Cash and cash equivalents $ 1,744,734 $ 2,644,306
Marketable securities 1,281,988 341,031
Accounts receivable less allowances (2001 -- $130,734 and 2000 -- $144,150) 2,743,040 2,740,272
Inventories 1,754,971 1,531,727
Other current assets including deferred taxes 2,242,020 2,923,475
---------------------------------
TOTAL CURRENT ASSETS 9,766,753 10,180,811
Property, plant and equipment:
Land 138,837 149,810
Buildings 3,294,004 2,694,612
Machinery and equipment 3,796,117 3,510,529
Construction in progress 1,715,493 1,223,282
---------------------------------
8,944,451 7,578,233
Less accumulated depreciation 2,662,291 2,543,409
---------------------------------
6,282,160 5,034,824
Goodwill and other intangibles, net of accumulated amortization
(2001 -- $1,895,670 and 2000 -- $1,739,368) 3,851,934 4,052,410
Other assets including deferred taxes 3,067,075 1,824,421
---------------------------------
TOTAL ASSETS $22,967,922 $21,092,466
=================================
----------------------------------------------------------------------------------------------------------------------------
LIABILITIES
Loans payable $ 2,097,354 $ 58,717
Trade accounts payable 672,457 595,233
Accrued expenses 4,257,523 8,831,459
Accrued federal and foreign taxes 229,847 256,650
---------------------------------
TOTAL CURRENT LIABILITIES 7,257,181 9,742,059
Long-term debt 7,357,277 2,394,790
Other noncurrent liabilities 3,355,793 5,226,495
Accrued postretirement benefits other than pensions 925,098 911,029
---------------------------------
----------------------------------------------------------------------------------------------------------------------------
STOCKHOLDERS' EQUITY
$2.00 convertible preferred stock, par value $2.50 per share; 5,000,000
shares authorized 51 55
Common stock, par value $0.33 1/3 per share; 2,400,000,000 shares authorized
(outstanding shares: 2001 -- 1,320,570,000 and 2000 -- 1,311,774,000) 440,190 437,258
Additional paid-in capital 4,295,051 3,952,457
Retained earnings (accumulated deficit) 170,309 (899,118)
Accumulated other comprehensive loss (833,028) (672,559)
---------------------------------
TOTAL STOCKHOLDERS' EQUITY 4,072,573 2,818,093
---------------------------------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $22,967,922 $21,092,466
=================================
The accompanying notes are an integral part of these Consolidated Financial
Statements.
34 Wyeth and Subsidiaries
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands except per share amounts)
[Enlarge/Download Table]
YEARS ENDED DECEMBER 31, 2001 2000 1999
-----------------------------------------------------------------------------------------------------------------------------------
NET REVENUE $ 14,128,514 $ 13,213,671 $ 11,815,138
----------------------------------------------------
Cost of goods sold 3,388,776 3,269,418 3,022,556
Selling, general and administrative expenses 5,179,285 4,983,465 4,322,207
Research and development expenses 1,869,679 1,687,889 1,587,505
Interest expense, net 146,358 57,562 213,866
Other income, net (274,331) (161,039) (255,697)
Gain on sale of Immunex common stock -- (2,061,204) --
Termination fee -- (1,709,380) --
Litigation charges 950,000 7,500,000 4,750,000
Goodwill impairment -- 401,000 --
Special charges -- 347,000 82,000
----------------------------------------------------
Income (loss) from continuing operations before
federal and foreign taxes 2,868,747 (1,101,040) (1,907,299)
Provision (benefit) for federal and foreign taxes 583,453 (200,000) (700,056)
----------------------------------------------------
INCOME (LOSS) FROM CONTINUING OPERATIONS 2,285,294 (901,040) (1,207,243)
Discontinued operations:
Income (loss) from operations of discontinued agricultural
products business (including federal and foreign taxes of
$57,289 and $1,551 for 2000 and 1999, respectively) -- 103,346 (19,878)
Loss on disposal of agricultural products business
(including federal and foreign tax charges of $855,248) -- (1,572,993) --
----------------------------------------------------
LOSS FROM DISCONTINUED OPERATIONS -- (1,469,647) (19,878)
----------------------------------------------------
NET INCOME (LOSS) $ 2,285,294 $ (2,370,687) $ (1,227,121)
====================================================
BASIC EARNINGS (LOSS) PER SHARE FROM CONTINUING OPERATIONS $ 1.74 $ (0.69) $ (0.92)
BASIC LOSS PER SHARE FROM DISCONTINUED OPERATIONS -- (1.12) (0.02)
----------------------------------------------------
BASIC EARNINGS (LOSS) PER SHARE $ 1.74 $ (1.81) $ (0.94)
====================================================
DILUTED EARNINGS (LOSS) PER SHARE FROM CONTINUING OPERATIONS $ 1.72 $ (0.69) $ (0.92)
DILUTED LOSS PER SHARE FROM DISCONTINUED OPERATIONS -- (1.12) (0.02)
----------------------------------------------------
DILUTED EARNINGS (LOSS) PER SHARE $ 1.72 $ (1.81) $ (0.94)
====================================================
The accompanying notes are an integral part of these Consolidated Financial
Statements.
Wyeth and Subsidiaries 35
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(In thousands except per share amounts)
[Enlarge/Download Table]
$2.00 RETAINED ACCUMULATED
CONVERTIBLE ADDITIONAL EARNINGS OTHER TOTAL
PREFERRED COMMON PAID-IN (ACCUMULATED COMPREHENSIVE STOCKHOLDERS'
STOCK STOCK CAPITAL DEFICIT) LOSS EQUITY
----------------------------------------------------------------------------------------------------------------------------------
Balance at January 1, 1999 $64 $437,466 $3,072,874 $ 6,432,729 $(328,337) $ 9,614,796
=====================================================================================
Net loss (1,227,121) (1,227,121)
Currency translation adjustments (285,963) (285,963)
Unrealized gains on marketable securities 815 815
-------------
Comprehensive loss (1,512,269)
-------------
Cash dividends declared:
Preferred stock (per share: $2.00) (50) (50)
Common stock (per share: $0.905) (1,183,571) (1,183,571)
Common stock acquired for treasury (6,409) (39,505) (1,012,385) (1,058,299)
Common stock issued for stock options 3,376 230,894 234,270
Conversion of preferred stock
and other exchanges (3) 206 128,442 (8,775) 119,870
-------------------------------------------------------------------------------------
BALANCE AT DECEMBER 31, 1999 61 434,639 3,392,705 3,000,827 (613,485) 6,214,747
=====================================================================================
----------------------------------------------------------------------------------------------------------------------------------
Net loss (2,370,687) (2,370,687)
Currency translation adjustments (70,496) (70,496)
Unrealized gains on marketable securities 11,422 11,422
-------------
Comprehensive loss (2,429,761)
-------------
Cash dividends declared:
Preferred stock (per share: $2.00) (46) (46)
Common stock (per share: $0.92) (1,201,431) (1,201,431)
Common stock acquired for treasury (2,472) (16,316) (374,289) (393,077)
Common stock issued for stock options 4,949 405,933 410,882
Conversion of preferred stock
and other exchanges (6) 142 170,135 (6,663) 163,608
International operations year end change 53,171 53,171
-------------------------------------------------------------------------------------
BALANCE AT DECEMBER 31, 2000 55 437,258 3,952,457 (899,118) (672,559) 2,818,093
=====================================================================================
----------------------------------------------------------------------------------------------------------------------------------
Net income 2,285,294 2,285,294
Currency translation adjustments (166,200) (166,200)
Unrealized gains on derivative contracts 7,865 7,865
Unrealized losses on marketable securities (2,134) (2,134)
-------------
Comprehensive income 2,124,825
-------------
Cash dividends declared:
Preferred stock (per share: $2.00) (42) (42)
Common stock (per share: $0.92) (1,211,012) (1,211,012)
Common stock issued for stock options 2,774 221,857 224,631
Conversion of preferred stock
and other exchanges (4) 158 120,737 (4,813) 116,078
-------------------------------------------------------------------------------------
BALANCE AT DECEMBER 31, 2001 $51 $440,190 $4,295,051 $ 170,309 $(833,028) $ 4,072,573
=====================================================================================
The accompanying notes are an integral part of these Consolidated Financial
Statements.
36 Wyeth and Subsidiaries
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
[Enlarge/Download Table]
YEARS ENDED DECEMBER 31, 2001 2000 1999
-----------------------------------------------------------------------------------------------------------------------------------
OPERATING ACTIVITIES
Income (loss) from continuing operations $ 2,285,294 $ (901,040) $(1,207,243)
Adjustments to reconcile income (loss) from continuing
operations to net cash provided from/(used for) operating
activities of continuing operations:
Litigation charges 950,000 7,500,000 4,750,000
Gain on sale of Immunex common stock -- (2,061,204) --
Goodwill impairment -- 401,000 --
Special charges -- 347,000 82,000
Gains on sales of assets (249,399) (159,430) (205,739)
Depreciation 426,590 336,239 341,871
Amortization 181,139 198,810 199,307
Deferred income taxes 267,820 (814,282) (1,410,068)
Diet drug litigation payments (7,257,882) (3,966,845) (117,581)
Contributions to defined benefit pension plans (429,710) (17,554) (14,259)
Deconsolidation of Immunex -- (236,768) --
Changes in working capital, net of businesses acquired,
sold or deconsolidated:
Accounts receivable (68,984) (433,182) 164,588
Inventories (273,063) 31,188 (115,699)
Other current assets (395,764) 179,817 (170,478)
Trade accounts payable and accrued expenses 277,009 270,518 (73,946)
Accrued federal and foreign taxes (14,654) (393,330) (121,227)
Other items, net (145,231) 196,405 391,851
----------------------------------------------------
Net cash provided from/(used for) continuing operations (4,446,835) 477,342 2,493,377
Net cash provided from/(used for) discontinued operations -- 77,600 (327,771)
----------------------------------------------------
NET CASH PROVIDED FROM/(USED FOR) OPERATING ACTIVITIES (4,446,835) 554,942 2,165,606
====================================================
-----------------------------------------------------------------------------------------------------------------------------------
INVESTING ACTIVITIES
Purchases of property, plant and equipment (1,924,265) (1,681,906) (937,435)
Proceeds from sale of agricultural products business -- 3,800,000 --
Proceeds from sale of Immunex common stock -- 2,404,875 --
Proceeds from sales of assets 408,230 256,192 327,730
Purchases of marketable securities (2,703,252) (677,802) (789,846)
Proceeds from sales and maturities of marketable securities 1,762,295 384,292 383,941
----------------------------------------------------
NET CASH PROVIDED FROM/(USED FOR) INVESTING ACTIVITIES (2,456,992) 4,485,651 (1,015,610)
====================================================
-----------------------------------------------------------------------------------------------------------------------------------
FINANCING ACTIVITIES
Net proceeds from/(repayments of) debt 7,007,156 (3,080,381) 1,593,468
Dividends paid (1,211,054) (1,201,477) (1,183,621)
Purchases of common stock for treasury -- (393,077) (1,058,299)
Exercises of stock options 224,631 410,882 234,270
----------------------------------------------------
NET CASH PROVIDED FROM/(USED FOR) FINANCING ACTIVITIES 6,020,733 (4,264,053) (414,182)
----------------------------------------------------
Effect of exchange rate changes on cash balances (16,478) (24,949) (25,418)
----------------------------------------------------
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (899,572) 751,591 710,396
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR 2,644,306 1,892,715 1,182,319
----------------------------------------------------
CASH AND CASH EQUIVALENTS, END OF YEAR $ 1,744,734 $ 2,644,306 $ 1,892,715
====================================================
The accompanying notes are an integral part of these Consolidated Financial
Statements.
Wyeth and Subsidiaries 37
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
PRINCIPLES OF CONSOLIDATION: The accompanying Consolidated Financial
Statements include the accounts of Wyeth (formerly American Home Products
Corporation) and its majority-owned subsidiaries (the Company). The financial
statements have been prepared in accordance with accounting principles generally
accepted in the United States and necessarily include amounts based on judgments
and estimates made by management.
Effective January 1, 2000, the financial results of certain pharmaceutical
subsidiaries in Japan and India, which previously were included on an equity
basis, were consolidated in the financial results of the Company due to changes
which gave the Company the ability to exercise control over the operations of
these affiliates. Also, effective January 1, 2000, the financial results of
Immunex Corporation (Immunex), which previously were consolidated, were
deconsolidated and included on an equity basis in the results of operations of
the Company (see Note 2).
Prior to 2000, certain of the Company's international affiliates reported
their results of operations on a one-month lag (year ended November 30), which
allowed more time to compile results. In December 2000, the one-month lag was
eliminated, primarily to reflect the results of these operations on a more
timely basis. As a result, December 2000 income from continuing operations for
these entities of $53.2 million was recorded directly to stockholders' equity.
DESCRIPTION OF BUSINESS: The Company is a U.S.-based multi-national
corporation engaged in the discovery, development, manufacture, distribution and
sale of a diversified line of products in two primary businesses:
Pharmaceuticals and Consumer Health Care. Pharmaceuticals include branded and
generic human ethical pharmaceuticals, biologicals, nutritionals, and animal
biologicals and pharmaceuticals. Principal products include women's health care
products, neuroscience therapies, cardiovascular products, infant nutritionals,
gastroenterology drugs, anti-infectives, vaccines, biopharmaceuticals, oncology
therapies, musculoskeletal therapies, hemophilia treatments and immunological
products. Principal animal health products include vaccines, pharmaceuticals,
endectocides and growth implants. Consumer Health Care products include
analgesics, cough/cold/allergy remedies, nutritional supplements, herbal
products, and hemorrhoidal, antacid, asthma and other relief items sold
over-the-counter. The Company sells its diversified line of products to
wholesalers, pharmacies, hospitals, physicians, retailers and other health care
institutions located in various markets in more than 140 countries throughout
the world. The Company is not dependent on any single customer or major group of
customers for its net revenue.
The Company is not dependent on any one patent-protected product or line of
products for a substantial portion of its net revenue or results of operations.
However, PREMARIN, one of the Company's conjugated estrogens products, which has
not had patent protection for many years, contributes significantly to net
revenue and results of operations.
EQUITY METHOD OF ACCOUNTING: The Company accounts for its investments in
20%- to 50%-owned companies using the equity method. Accordingly, the Company's
share of the earnings of these companies is included in Other income, net. The
related equity investment is included in Other assets including deferred taxes.
At December 31, 2001, Immunex was the Company's only material equity investment.
Immunex is a biopharmaceutical company that discovers, manufactures and markets
therapeutic products for the treatment of cancer and musculoskeletal disorders
such as rheumatoid arthritis. See Note 2 for discussion of Immunex-related
transactions in 2001 and 2000.
CASH EQUIVALENTS consist primarily of certificates of deposit, time deposits
and other short-term, highly liquid securities with original maturities of three
months or less and are stated at cost. The carrying value of cash equivalents
approximates fair value due to the short-term, highly liquid nature of cash
equivalents.
MARKETABLE SECURITIES consist of U.S. government or agency issues, commercial
paper, time deposits and corporate bonds and are stated at fair value, which
approximates cost due to the short-term, highly liquid nature of these
securities (less than six months). All marketable securities are
available-for-sale investments. The fair values are estimated based on current
market prices.
INVENTORIES are valued at the lower of cost or market. Inventories valued
under the last-in, first-out (LIFO) method amounted to $319.9 million and $325.1
million at December 31, 2001 and 2000, respectively. The current value exceeded
the LIFO value by $59.5 million and $59.7 million at December 31, 2001 and 2000,
respectively. The remaining inventories are valued primarily under the first-in,
first-out (FIFO) method.
Inventories at December 31 consisted of:
[Download Table]
(In thousands) 2001 2000
--------------------------------------------------------------------------------
Finished goods $ 653,108 $ 585,123
Work in progress 674,636 586,656
Materials and supplies 427,227 359,948
-------------------------------
$1,754,971 $1,531,727
===============================
PROPERTY, PLANT AND EQUIPMENT is carried at cost. Depreciation is provided
over the estimated useful lives of the related assets placed into service,
principally on the straight-line method.
GOODWILL AND OTHER INTANGIBLES: Goodwill is defined as the excess of cost
over the fair value of net assets acquired and is amortized using the
straight-line method over various periods ranging from 15 to 40 years. Other
intangibles are recorded at cost and amortized from three to 10 years. The
Company continually reviews goodwill and other intangibles to evaluate whether
changes have occurred that would suggest such assets may be impaired. If
circumstances suggest an impairment, undiscounted
38 Wyeth and Subsidiaries
future cash flows of such assets acquired or purchased are estimated. If this
estimate indicates that goodwill or other intangibles are not recoverable, the
carrying value of the goodwill or other intangibles is reduced to fair value by
the estimated shortfall of future cash flows on a discounted basis.
As of January 1, 2002, the Company will implement new authoritative
accounting guidance relating to both the initial recording and subsequent
impairment testing of goodwill and other intangibles. Refer to "Recently Issued
Accounting Standards" herein for discussion of the Company's implementation of
this new guidance.
DERIVATIVE FINANCIAL INSTRUMENTS: The Company currently manages its exposure
to certain market risks, including foreign exchange and interest rate risks,
through the use of derivative financial instruments, and accounts for them in
accordance with Statement of Financial Accounting Standards (SFAS) Nos. 133,
Accounting for Derivative Instruments and Hedging Activities, and 138,
Accounting for Certain Derivative Instruments and Certain Hedging Activities.
On the date that the Company enters into a derivative contract, it designates
the derivative as: (1) a hedge of the fair value of a recognized asset or
liability (fair value hedge), (2) a hedge of a forecasted transaction or the
variability of cash flows that are to be received or paid in connection with a
recognized asset or liability (cash flow hedge), (3) a foreign currency fair
value or cash flow hedge (foreign currency hedge) or (4) a derivative instrument
that is not designated for hedge accounting treatment. For derivative contracts
that are designated and qualify as fair value hedges (including foreign currency
fair value hedges), the derivative instrument is marked-to-market with gains and
losses recognized in current period earnings to offset the respective losses and
gains recognized on the underlying exposure. For derivative contracts that are
designated and qualify as cash flow hedges (including foreign currency cash flow
hedges), the effective portion of gains and losses on these contracts is
reported as a component of accumulated other comprehensive income (loss) and
reclassified into earnings in the same period the hedged transaction affects
earnings. Any hedge ineffectiveness on cash flow hedges is immediately
recognized in earnings. The Company also enters into derivative contracts that
are not designated as hedging instruments. These derivative contracts are
recorded at fair value with the gain or loss recognized in current period
earnings. The Company does not hold any derivative instruments for trading
purposes. See Note 7 for further description of the Company's specific programs
to manage risk using derivative financial instruments.
CURRENCY TRANSLATION: The majority of the Company's international operations
are translated into U.S. dollars using current foreign currency exchange rates
with currency translation adjustments reflected in Accumulated other
comprehensive loss in stockholders' equity. Currency translation adjustments
comprise the majority of Accumulated other comprehensive loss on the
Consolidated Balance Sheets and the Consolidated Statements of Changes in
Stockholders' Equity. Currency translation adjustments related to international
operations in highly inflationary economies are included in the results of
operations.
REVENUE RECOGNITION: Revenue from the sale of Company products is recognized
in Net revenue upon shipment to customers. Provisions for certain rebates,
product returns and discounts to customers are provided for as reductions in
determining Net revenue in the same period the related sales are recorded.
Revenue under co-promotion agreements from the sale of products developed by
other companies, such as the Company's arrangement with Immunex to co-promote
ENBREL and with King Pharmaceuticals, Inc. to co-promote ALTACE, is recorded as
alliance revenue, which is included in Net revenue. Such alliance revenue is
earned when the co-promoting company ships the product to a third party. Selling
and marketing expenses related to alliance revenue are included in Selling,
general and administrative expenses.
SHIPPING AND HANDLING COSTS, which include transportation to customers,
transportation to distribution points, warehousing and handling costs, are
included in Selling, general and administrative expenses. The Company typically
does not charge customers for shipping and handling costs. Shipping and handling
costs were $228.9 million, $212.5 million and $204.5 million in 2001, 2000 and
1999, respectively.
REBATES AND SALES INCENTIVES, which are deducted to arrive at Net revenue,are
offered to customers based upon volume purchases, the attainment of market share
levels, sales support, government mandates, coupons and consumer discounts.
Rebates and sales incentives accruals included in Accrued expenses at December
31, 2001 and 2000 were $615.0 million and $482.7 million, respectively.
Wyeth and Subsidiaries 39
EARNINGS (LOSS) PER SHARE: The following table sets forth the
computations of basic earnings (loss) per share and diluted earnings (loss) per
share:
[Download Table]
(In thousands except per share amounts)
YEARS ENDED DECEMBER 31, 2001 2000 1999
--------------------------------------------------------------------------------
Income (loss) from continuing
operations less preferred
dividends $2,285,252 $ (901,086) $(1,207,293)
Loss from
discontinued operations -- (1,469,647) (19,878)
--------------------------------------------
Net income (loss) less
preferred dividends $2,285,252 $(2,370,733) $(1,227,171)
Denominator:
Weighted average common
shares outstanding 1,317,102 1,306,474 1,308,876
--------------------------------------------
Basic earnings (loss) per share
from continuing operations $ 1.74 $ (0.69) $ (0.92)
Basic loss per share from
discontinued operations -- (1.12) (0.02)
--------------------------------------------
Basic earnings (loss) per share $ 1.74 $ (1.81) $ (0.94)
============================================
Income (loss) from continuing
operations $2,285,294 $ (901,040) $(1,207,243)
Loss from
discontinued operations -- (1,469,647) (19,878)
--------------------------------------------
Net income (loss) $2,285,294 $(2,370,687) $(1,227,121)
Denominator:
Weighted average common
shares outstanding 1,317,102 1,306,474 1,308,876
Common stock equivalents
of outstanding stock options
and deferred contingent
common stock awards* 13,707 -- --
--------------------------------------------
Total shares* 1,330,809 1,306,474 1,308,876
--------------------------------------------
Diluted earnings (loss) per
share from continuing
operations* $ 1.72 $ (0.69) $ (0.92)
Diluted loss per share from
discontinued operations* -- (1.12) (0.02)
--------------------------------------------
Diluted earnings (loss)
per share* $ 1.72 $ (1.81) $ (0.94)
============================================
* The total weighted average common shares outstanding for diluted loss
per share for 2000 and 1999 did not include common stock equivalents,
as the effect would have been antidilutive.
RECENTLY ISSUED ACCOUNTING STANDARDS: In June 2001, the Financial Accounting
Standards Board (FASB) issued SFAS No. 142, Goodwill and Other Intangible
Assets, which supersedes APB Opinion No. 17, Intangible Assets, and addresses
how intangible assets that are acquired individually or with a group of other
assets should be accounted for in financial statements upon their acquisition.
The statement also addresses how goodwill and other intangibles should be
accounted for after they have been initially recognized in the financial
statements. With the adoption of SFAS No. 142, goodwill no longer is amortized
over its estimated useful life but is subject to at least an annual assessment
for impairment by applying a fair-value-based test. The same applies to other
intangibles, which have been determined to have indefinite useful lives. Other
intangibles with finite lives will continue to be amortized. The Company will
adopt SFAS No. 142 as of January 1, 2002.
In accordance with the adoption of SFAS No. 142, as of January 1, 2002, the
Company will cease amortizing goodwill. Included in Selling, general and
administrative expenses for 2001 was approximately $160.5 million ($153.9
million after-tax or $0.12 per share-diluted) of goodwill amortization. The
Company currently is assessing the impact the new impairment testing
requirements may have on its financial position, results of operations and cash
flows.
In October 2001, the FASB issued SFAS No. 144, Accounting for the Impairment
or Disposal of Long-Lived Assets, which superseded existing guidance. The
provisions of SFAS No. 144 are effective for fiscal years beginning after
December 15, 2001 and generally are to be applied prospectively. SFAS No. 144
augments the criteria that would have to be met to classify an asset as
held-for-sale and refines the guidance in determining fair value in measuring an
impairment. The statement also requires expected future operating losses from
discontinued operations to be recorded in the period in which the losses are
incurred (rather than as of the date management commits to a formal plan to
dispose of a segment, as was previously required). In addition, the
qualifications for dispositions to be considered discontinued operations have
been expanded. The Company adopted this statement on January 1, 2002 and will
prospectively comply with all criteria outlined in SFAS No. 144.
In April 2001, the Emerging Issues Task Force (EITF) reached a consensus on
Issue No. 00-25, Vendor Income Statement Characterization of Consideration Paid
to a Reseller of the Vendor's Products. EITF No. 00-25 requires the cost of
certain vendor considerations to be classified as a reduction of revenue rather
than a marketing expense. The Company will adopt the provisions of EITF No.
00-25 as of January 1, 2002. The adoption of EITF No. 00-25 will result in
reclassifications of certain marketing expenses to revenues and will have no
effect on income from continuing operations. The Company does not anticipate the
adoption of this consensus to significantly affect the growth rate of net
revenues.
RECLASSIFICATIONS: Certain reclassifications have been made to the December
31, 2000 and 1999 Consolidated Financial Statements to conform with the December
31, 2001 presentation.
2. ACQUISITIONS, DIVESTITURES AND DISCONTINUED OPERATIONS
Discontinued Operations -- Cyanamid Agricultural Products
On March 20, 2000, the Company signed a definitive agreement with BASF
Aktiengesellschaft (BASF) to sell the Cyanamid
40 Wyeth and Subsidiaries
Agricultural Products business which manufactures, distributes and sells crop
protection and pest control products worldwide. On June 30, 2000, the sale was
completed, and BASF paid the Company $3,800.0 million in cash and assumed
certain debt. The Company recorded an after-tax loss on the sale of this
business of $1,573.0 million or $1.20 per share-diluted and reflected this
business as a discontinued operation in the 2000 first quarter. The loss on the
sale included closing costs from the transaction and reflected operating income
of the discontinued business from April 1, 2000 through June 30, 2000 (the
disposal date). The loss on the sale was due primarily to a difference in the
basis of the net assets sold for financial reporting purposes compared with the
Company's basis in such net assets for tax purposes. This difference related,
for the most part, to goodwill, which is not recognized for tax purposes. As a
result, the transaction generated a taxable gain requiring the recording of a
tax provision, in addition to a book loss related to a write-off of net assets
in excess of the selling price. The Consolidated Financial Statements and
related Notes for the period ended December 31, 1999 have been restated, where
applicable, to reflect the Cyanamid Agricultural Products business as a
discontinued operation.
Operating results of discontinued operations were as follows:
(In thousands except per share amounts)
[Enlarge/Download Table]
STATEMENT OF OPERATIONS
-------------------------
Years Ended December 31, 2000 1999
--------------------------------------------------------------------------------------
Net revenue $ 546,790 $1,668,980
----------------------------
Income (loss) before federal and foreign taxes 160,635 (18,327)
Provision for federal and foreign taxes 57,289 1,551
----------------------------
Income (loss) from operations of discontinued
agricultural products business 103,346 (19,878)
Loss on disposal of agricultural products
business (including federal and foreign
tax charges of $855,248) (1,572,993) --
----------------------------
Loss from discontinued operations $(1,469,647) $ (19,878)
============================
Diluted loss per share from
discontinued operations $ (1.12) $ (0.02)
============================
Immunex Transactions:
2001 Proposed Acquisition of Immunex by Amgen
In December 2001, Amgen Inc. and Immunex signed a definitive agreement providing
for Amgen, the world's largest biotechnology company, to acquire Immunex in a
merger transaction. Under the terms of the agreement, each share of Immunex
common stock will be exchanged for 0.44 shares of Amgen common stock and $4.50
in cash. The transaction has been structured as a tax-free reorganization, and
Immunex shareholders will not be taxed to the extent that they receive Amgen
stock.
As part of the agreement, Amgen will acquire the 41% ownership in Immunex
held by the Company at December 31, 2001 for the same consideration per share,
providing the Company with over $1,000.0 million in cash and approximately an 8%
ownership in Amgen. The Company has agreed to vote its shares in favor of the
transaction. The transaction is anticipated to close in the second half of 2002,
subject to approval by shareholders of both companies, as well as customary
regulatory approvals. The Company and Immunex co-promote ENBREL in the United
States and Canada with the Company having exclusive international rights to the
product. The financial aspects of the existing licensing and marketing rights to
ENBREL remain unchanged.
2000 Transactions in Immunex Common Stock
In October 2000, the Company increased its ownership in Immunex from
approximately 53% to approximately 55% by converting a $450.0 million
convertible subordinated note into 15,544,041 newly issued shares of common
stock of Immunex. In November 2000, through a public equity offering, the
Company sold 60.5 million shares of Immunex common stock, and Immunex sold 20
million shares of newly issued Immunex common stock. Proceeds to the Company
were approximately $2,404.9 million resulting in a gain on the sale of $2,061.2
million ($1,414.9 million after-tax or $1.08 per share-diluted). Included in the
gain on the sale was a noncash pre-tax gain of $303.2 million ($200.2 million
after-tax), representing the Company's increase in its proportionate share of
the net book value of Immunex from Immunex's issuance of 20 million shares of
its common stock at a price above the net book value per share owned by the
Company. The Company used the net proceeds from the sale of its Immunex common
stock to reduce outstanding commercial paper and for other general corporate
purposes.
The public equity offering reduced the Company's ownership in Immunex from
approximately 55% to approximately 41%, which represented the ownership at
December 31, 2001 and 2000. As a result of the reduction in ownership below 50%,
the Company included the financial results of Immunex on an equity basis
retroactive to January 1, 2000.
3. TERMINATION FEE, GOODWILL IMPAIRMENT AND SPECIAL CHARGES
Termination Fee
On November 3, 1999, the Company and Warner-Lambert Company entered into an
agreement to combine the two companies in a merger-of-equals transaction. On
February 6, 2000, the merger agreement was terminated. The Company recorded
income of $1,709.4 million ($1,111.1 million after-tax or $0.85 per
share-diluted) resulting from the receipt of a $1,800.0 million termination fee
provided for under the merger agreement offset, in part, by certain related
expenses.
Goodwill Impairment
Based on projected profitability and future cash flows associated with generic
pharmaceuticals and the SOLGAR consumer health care product line, it was
determined that goodwill related to
Wyeth and Subsidiaries 41
these product lines, at December 31, 2000, was impaired. As a result, the
Company recorded a charge of $401.0 million ($341.0 million after-tax or $0.26
per share-diluted) in 2000 to write down the carrying value of goodwill, to fair
value, based upon discounted future cash flows.
Special Charges:
Voluntary Market Withdrawals
In November 2000, the U.S. Food and Drug Administration (FDA) requested that the
pharmaceutical industry voluntarily stop producing and distributing products
containing phenylpropanolamine (PPA). The Company immediately ceased global
production and shipments of any products containing PPA and voluntarily withdrew
any such products from customer warehouses and retail store shelves. As a
result, the Company recorded a special charge of $80.0 million ($52.0 million
after-tax or $0.04 per share-diluted) to provide primarily for product returns
and the write-off of inventory. The Company already had reformulated a majority
of the products involved in the voluntary market withdrawal and began shipping
these products in the United States at the end of November 2000. At December 31,
2001, all amounts provided for the PPA voluntary market withdrawal had been
utilized.
During the 1999 second quarter, the Company recorded a special charge
aggregating $82.0 million ($53.0 million after-tax or $0.04 per share-diluted)
for estimated costs associated with the suspension of shipments and the
voluntary market withdrawal of ROTASHIELD, the Company's rotavirus vaccine. At
December 31, 2001, all amounts provided for the ROTASHIELD voluntary market
withdrawal had been utilized.
Product Discontinuations
During the 2000 fourth quarter, the Company recorded a special charge of $267.0
million ($173.0 million after-tax or $0.13 per share-diluted) related to the
discontinuation of certain products manufactured at the Company's Marietta,
Pennsylvania and Pearl River, New York facilities. Approximately $227.1 million
related to noncash costs for fixed asset impairments and inventory write-offs,
with the remainder of the charge covering severance obligations, idle plant
costs and contract termination costs. During 2001, approximately $7.8 million of
these costs were paid, leaving an accrual of $32.1 million at December 31, 2001.
The timing of the remaining costs to be incurred has been delayed as the Company
has continued to produce certain products in response to a potential market
shortage for these products and the related medical necessity. As a result, the
majority of the remaining costs will not be expended until 2003.
Restructuring Charge and Related Asset Impairments
In December 1998, the Company recorded a special charge for restructuring and
related asset impairments of $321.2 million ($224.8 million after-tax or $0.17
per share-diluted) to recognize the costs of the reorganization of the
pharmaceutical and nutritional supply chains (primarily in the Asian-Pacific and
Latin American regions), the reorganization of the U.S. pharmaceutical and
consumer health care distribution systems, and a reduction in personnel from the
globalization of certain business units. The reorganization of the
pharmaceutical and nutritional supply chains will result in the closure of 14
plants (nine pharmaceutical and five nutritional). The reorganization of the
U.S. pharmaceutical and consumer health care distribution systems resulted in
the closure of three distribution centers. The restructuring ultimately will
result in the elimination of 3,900 positions offset, in part, by 1,000 newly
created positions in the same functions at other locations. The components of
this charge were as follows: (i) personnel costs of $120.0 million, (ii) noncash
costs for fixed asset write-offs of $115.2 million and (iii) other closure/exit
costs of $86.0 million. The noncash costs of $115.2 million reduced the carrying
value of the fixed assets to their estimated fair value, taking into
consideration depreciation expected during the transition period, which was
determined by experience with similar properties and external appraisals. These
fixed assets, with a fair value of $11.6 million, have remained operational
during the transition period of obtaining the necessary regulatory approvals to
relocate these operations to new and existing facilities. Since these fixed
assets have remained in use, depreciation was not suspended and will be
recognized over the transition period. Other closure/exit costs are a direct
result of the restructuring plan. The majority of the other closure/exit costs
are anticipated to be paid after the facilities cease production and prior to
disposition. These costs include non-cancelable operating leases, security,
utilities, maintenance, property taxes and other related costs that will be paid
during the disposal period. Due to the specialized nature of these facilities,
the majority of the costs will be paid over a two- to three-year period as
product transfers are approved by regulatory authorities and manufacturing sites
are closed. However, delays in obtaining certain regulatory approvals and other
closure delays will cause certain costs to be paid after that period.
At December 31, 2001, approximately 3,700 positions had been eliminated, and
two distribution centers owned by the Company and a leased distribution center
had been closed. Of 14 manufacturing plants originally anticipated to be closed,
eight were closed in 2000 and two were closed during 2001. The Company currently
anticipates utilizing the remainder of the restructuring accruals in 2002,
assuming no further delays in regulatory approvals.
42 Wyeth and Subsidiaries
Activity in the restructuring accruals from continuing operations was as
follows:
[Enlarge/Download Table]
PERSONNEL FIXED ASSET OTHER CLOSURE/
(In thousands) COSTS WRITE-OFFS EXIT COSTS TOTAL
------------------------------------------------------------------------------------------------------
Restructuring accruals at inception $ 119,975 $ 115,225 $ 86,000 $ 321,200
Cash expenditures (527) -- (922) (1,449)
Write-offs of fixed assets -- (115,225) -- (115,225)
------------------------------------------------------
Restructuring accruals at December 31, 1998 119,448 -- 85,078 204,526
Cash expenditures (64,695) -- (5,817) (70,512)
------------------------------------------------------
Restructuring accruals at December 31, 1999 54,753 -- 79,261 134,014
Cash expenditures (48,504) -- (19,626) (68,130)
------------------------------------------------------
Restructuring accruals at December 31, 2000 6,249 -- 59,635 65,884
Redistributions 14,000 -- (14,000) --
Cash expenditures (11,212) -- (15,016) (26,228)
------------------------------------------------------
Restructuring accruals at December 31, 2001 $ 9,037 $ -- $ 30,619 $ 39,656
======================================================
During the 2001 second quarter, the Company made redistribution adjustments
between categories to increase accrual balances for personnel costs by $14.0
million and to decrease other closure/exit costs by $14.0 million. These
redistributions were necessary due to higher than expected enhanced pension
benefits and outplacement costs for non-U.S. employees, updated forecasts of
employees within the affected facilities, and lower than expected other
closure/exit costs. The original scope of the restructuring program remains
substantially unchanged.
4. DEBT AND FINANCING ARRANGEMENTS
The Company's debt at December 31 consisted of:
[Download Table]
(In thousands) 2001 2000
-----------------------------------------------------------------------------
Commercial paper $4,817,205 $ 798,029
Notes payable:
6.50% notes due 2002 250,000 250,000
5.875% notes due 2004 500,000 --
7.90% notes due 2005 1,000,000 1,000,000
6.25% notes due 2006 1,000,000 --
6.70% notes due 2011 1,500,000 --
7.25% debentures due 2023 250,000 250,000
Pollution control and industrial revenue bonds:
1.8% - 5.8% due 2006 - 2020 83,950 85,150
Other debt:
0.5% - 17.0% due 2002 - 2009 40,674 70,328
Fair value of interest rate swaps 12,802 --
-----------------------------
9,454,631 2,453,507
Less current portion 2,097,354 58,717
-----------------------------
$7,357,277 $2,394,790
=============================
The fair value of the Company's outstanding debt was $9,607.7 million and
$2,506.6 million at December 31, 2001 and 2000, respectively. The fair value of
the Company's outstanding debt was estimated based on market prices.
The weighted average interest rate on the commercial paper outstanding at
December 31, 2001 and 2000 was 2.09% and 6.45%, respectively. The commercial
paper had original maturities that did not exceed 270 days and a weighted
average remaining maturity of 37 days and 35 days at December 31, 2001 and 2000,
respectively.
Revolving Credit Facilities
The Company maintains a $2,000.0 million credit facility, which supports
borrowings under the commercial paper program and terminates on July 31, 2002.
Since the $2,000.0 million credit facility terminates in less than one year,
commercial paper outstanding of $1,817.2 million, supported by this facility,
was classified as current debt in Loans payable as of December 31, 2001.
In addition, in March 2001, the Company obtained new credit facilities
totaling $6,000.0 million. The new credit facilities included a $3,000.0
million, 364-day credit facility (which also supports borrowings under the
commercial paper program) and a 364-day bridge facility to capital markets,
which was terminated on March 30, 2001 as discussed below. Any borrowings under
the new 364-day credit facility that are outstanding upon its termination in
March 2002 are extendible for an additional year. The portion of commercial
paper outstanding at December 31, 2001 supported by the $3,000.0 million,
364-day credit facility was classified as Long-term debt since the Company
intends, and has the ability, to refinance these obligations through the
issuance of additional commercial paper or through the use of its $3,000.0
million credit facility as described above.
The proceeds from the credit facilities may be used to support commercial
paper and the Company's general corporate and working capital requirements,
including payments related to the REDUX and PONDIMIN diet drug litigation. The
credit facilities contain substantially identical financial and other covenants,
representations, warranties, conditions and default provisions. At December 31,
2001 and 2000, there were no borrowings outstanding under the facilities.
Wyeth and Subsidiaries 43
In March 2002, subsequent to the date of the "Report of Independent Public
Accountants," the Company renewed the $3,000.0 million credit facility for an
additional 364-day term and reduced the $2,000.0 million credit facility to
$1,000.0 million until it matures on July 31, 2002.
Bridge Facility and Notes
The new credit facilities also included a $3,000.0 million, 364-day bridge
facility, which was terminated when the Company issued $3,000.0 million of
Senior Notes (the Notes) on March 30, 2001. These Notes consisted of three
tranches, which pay interest semiannually on March 15 and September 15, in a
transaction exempt from registration under the Securities Act of 1933, as
amended (the Securities Act), pursuant to Rule 144A, as follows:
- $500.0 million 5.875% Notes due March 15, 2004
- $1,000.0 million 6.25% Notes due March 15, 2006
- $1,500.0 million 6.70% Notes due March 15, 2011
As of June 15, 2001, pursuant to an exchange offer made by the Company,
substantially all the Notes had been exchanged for new notes which have
substantially identical terms and which have been registered under the
Securities Act.
The interest rate payable on each series of Notes is subject to an increase
of 0.25 percentage points per level of downgrade in the Company's credit rating
by Moody's or S&P. However, the total adjustment to the interest rate for the
series of Notes cannot exceed two percentage points. There is no adjustment to
the interest rate payable on each series of Notes for the first single level
downgrade in the Company's credit rating by S&P. In the case of the $1,500.0
million 6.70% Notes, the interest rate in effect on March 15, 2006 for such
Notes will, thereafter, become the effective interest rate until maturity on
March 15, 2011. The Company would incur a total of approximately $7.5 million of
additional annual interest expense for every 0.25 percentage point increase in
the interest rate. If Moody's or S&P subsequently were to increase the Company's
credit rating, the interest rate payable on each series of Notes is subject to a
decrease of 0.25 percentage points for each level of credit rating increase. The
interest rate payable for the series of Notes cannot be reduced below the
original coupon rate of each series of Notes.
The Company entered into two $750.0 million notional amount interest rate
swaps relating to the $1,500.0 million 6.70% Notes under which the Company
effectively converted the fixed rate on these Notes to a floating rate of
interest which is based on LIBOR. See Note 7 for further discussion of the
interest rate swaps.
In addition to the $3,000.0 million of Notes described above, the Company has
outstanding the following non-callable, unsecured and unsubordinated debt
instruments:
- $250.0 million 6.50% Notes due October 2002, interest payments due on April
15 and October 15
- $1,000.0 million 7.90% Notes due February 2005, interest payments due on
February 15 and August 15
- $250.0 million 7.25% debentures due March 2023, interest payments due on
March 1 and September 1
The aggregate maturities of debt during the next five years and thereafter at
December 31, 2001 are as follows:
[Download Table]
(In thousands)
--------------------------------------------------------------------------------
2002 $2,097,354
2003 7,929
2004 505,917
2005 1,001,380
2006 1,012,480
Thereafter 1,829,571
---------
6,454,631
Commercial paper classified as Long-term debt 3,000,000
---------
Total debt $9,454,631
==========
Interest payments in connection with the Company's debt obligations for the
years ended December 31, 2001, 2000 and 1999 amounted to $331.7 million, $343.0
million and $294.8 million, respectively.
Interest expense, net included interest income of $154.8 million, $181.3
million and $129.4 million in 2001, 2000 and 1999, respectively. Interest
capitalized in connection with capital projects was $94.3 million, $43.3 million
and $15.4 million in 2001, 2000 and 1999, respectively.
5. OTHER NONCURRENT LIABILITIES
Other noncurrent liabilities include reserves for the REDUX and PONDIMIN
litigation (see Note 12), reserves relating to income taxes, environmental
matters, product liability and other litigation, as well as restructuring,
pension and other employee benefit liabilities, and minority interests.
The Company has responsibility for environmental, safety and cleanup
obligations under various local, state and federal laws, including the
Comprehensive Environmental Response, Compensation and Liability Act, commonly
known as Superfund. At December 31, 2001, the Company was a party to, or
otherwise involved in, legal proceedings directed at the cleanup of 53 Superfund
sites.
It is the Company's policy to accrue for environmental cleanup costs if it is
probable that a liability has been incurred and an amount is reasonably
estimable. In many cases, future environmental-related expenditures cannot be
quantified with a reasonable degree of accuracy. Environmental expenditures that
relate to an existing condition caused by past operations that do not contribute
to current or future results of operations are expensed. As investigations and
cleanups proceed, environmental-related liabilities are reviewed and adjusted as
additional information becomes available. The aggregate environmental-related
accruals were $364.2 million and $378.6 million at December 31, 2001 and 2000,
respectively. Environmental-related accruals have been recorded without giving
effect to any possible future
44 Wyeth and Subsidiaries
insurance proceeds or the timing of payments. See Note 12 for discussion of
contingencies.
In 2000, the Company introduced a new incentive program to employees, the
Performance Incentive Award Program (PIA), which awards employees based on the
Company's operating results and the individual employee's performance.
Substantially all U.S. and Puerto Rico exempt employees, who are not subject to
other incentive programs, and key international employees are eligible to
receive cash awards under PIA. The value of PIA awards for 2001 and 2000 was
$117.3 million and $94.7 million, respectively. In 1999, cash bonuses totaling
$38.8 million were paid to key employees. Through 1998, the Company provided
incentive awards under the Management Incentive Plan (MIP), which provided for
cash and deferred contingent common stock awards to key employees. Deferred
contingent common stock awards plus accrued dividends, related to the MIP
program, totaling 875,206 shares were outstanding at December 31, 2001.
6. PENSIONS AND OTHER POSTRETIREMENT BENEFITS
PENSIONS: The Company sponsors various retirement plans for most full-time
employees. These defined benefit and defined contribution plans cover all U.S.
and certain international locations. Total pension expense from continuing
operations for both defined benefit and defined contribution plans for 2001,
2000 and 1999 was $141.9 million, $107.7 million and $95.5 million,
respectively. Pension expense from continuing operations for defined
contribution plans for 2001, 2000 and 1999 totaled $67.0 million, $62.9 million
and $61.6 million, respectively.
Pension plan benefits for defined benefit plans are based primarily on
participants' compensation and years of credited service. Investment
responsibility for the pension plan assets is assigned to outside investment
managers and is limited to certain asset allocation criteria and investment
guidelines established by the Company. Employees do not have any ability to
determine the investment allocation of the pension plan assets.
Generally, contributions to defined contribution plans are based on a
percentage of the employee's compensation. The Company's 401(k) savings plans
have been established for substantially all U.S. employees. Certain employees
are eligible to enroll in the plan on their hire date and can contribute between
1% and 16% of their annual pay. The Company provides a matching contribution to
eligible participants of 50% on the first 6% of annual pay contributed to the
plan, or a maximum of 3% of annual pay. Employees can direct their contributions
and the Company's matching contributions into any of the funds offered. These
funds provide participants with a cross section of investing options, including
the Company's common stock. All contributions to the Company's common stock,
whether by employee or employer, can be transferred to other fund choices daily.
OTHER POSTRETIREMENT BENEFITS: The Company provides postretirement health
care and life insurance benefits for retired employees of most domestic
locations and Canada. Most full-time employees become eligible for these
benefits after attaining specified age and service requirements.
Although the Company sold the Cyanamid Agricultural Products business in 2000
(see Note 2), which was accounted for as a discontinued operation, the pensions
and other postretirement benefits were excluded from the sale for U.S. plans
since employees of the Cyanamid Agricultural Products business accrued benefits
in plans that encompassed other business segments. Except for one pension plan
in Germany, all international plans will continue to be maintained by the
Company to pay benefits that were accrued prior to the sale. Accordingly,
projected benefit obligations, fair value of plan assets and (prepaid)/accrued
benefit costs were not restated, except to reflect the sale of the pension plan
in Germany. However, components of net periodic benefit cost from continuing
operations were restated to reflect the Cyanamid Agricultural Products business
as a discontinued operation.
The change in projected benefit obligation, change in plan assets,
reconciliation of funded status and amounts recognized in the Consolidated
Balance Sheets for the Company's defined benefit plans (principally U.S. plans)
for 2001 and 2000 were as follows:
[Enlarge/Download Table]
PENSIONS OTHER POSTRETIREMENT BENEFITS
----------------------------- --------------------------------
CHANGE IN PROJECTED BENEFIT OBLIGATION (In thousands) 2001 2000 2001 2000
---------------------------------------------------------------------------------------------------------------------------
Projected benefit obligation at January 1 $3,210,575 $3,005,665 $1,020,330 $1,076,298
Consolidation of Japan benefit plan -- 186,327 -- --
Service cost 78,634 74,656 24,179 20,460
Interest cost 226,786 225,248 76,966 77,666
Service and interest cost -- discontinued operations -- 3,074 -- 2,189
Amendments 9,796 11,235 -- 16,952
Net actuarial loss/(gain) 104,938 71,158 227,758 (72,589)
Curtailments/settlements -- (39,826) -- (24,289)
Benefits paid (284,603) (296,613) (78,516) (75,900)
Currency translation adjustment (30,094) (30,349) (632) (457)
--------------------------------------------------------------
Projected benefit obligation at December 31 $3,316,032 $3,210,575 $1,270,085 $1,020,330
==============================================================
Wyeth and Subsidiaries 45
\
[Enlarge/Download Table]
PENSIONS OTHER POSTRETIREMENT BENEFITS
---------------------------- -----------------------------
CHANGE IN PLAN ASSETS (In thousands) 2001 2000 2001 2000
-----------------------------------------------------------------------------------------------------------
Fair value of plan assets at January 1 $ 2,816,016 $ 3,001,154 -- --
Consolidation of Japan benefit plan -- 76,089 -- --
Actual return on plan assets (213,908) 34,607 -- --
Amendments 6,754 -- -- --
Company contributions 429,710 17,554 $ 78,516 $ 75,900
Benefits paid (284,603) (296,613) (78,516) (75,900)
Currency translation adjustment (15,347) (16,775) -- --
--------------------------------------------------------------
Fair value of plan assets at December 31 $ 2,738,622 $ 2,816,016 $ -- $ --
==============================================================
[Enlarge/Download Table]
PENSIONS OTHER POSTRETIREMENT BENEFITS
(In thousands) -------------------------- -----------------------------
RECONCILIATION OF FUNDED STATUS 2001 2000 2001 2000
-----------------------------------------------------------------------------------------------------------
Funded status $ 577,410 $ 394,559 $ 1,270,085 $ 1,020,330
Unrecognized net actuarial loss (603,051) (44,225) (243,292) (15,603)
Unrecognized prior service cost (57,193) (60,502) (16,695) (18,698)
Unrecognized net transition obligation (5,301) (8,266) -- --
----------------------------------------------------------------
(Prepaid)/accrued benefit costs $ (88,135) $ 281,566 $ 1,010,098 $ 986,029
================================================================
[Download Table]
PENSIONS
(In thousands) ----------------------------
AMOUNTS RECOGNIZED IN THE
CONSOLIDATED BALANCE SHEETS 2001 2000
-----------------------------------------------------------------------
Prepaid benefit cost $ (212,967) $ (8,537)
Accrued benefit liability 124,832 290,103
In December 2001, the Company made a $400.0 million funding contribution to
the U.S. Non-bargaining defined benefit pension plan (largest U.S. plan) due
primarily to the decrease in the plan assets and, as a result, the anticipation
of future statutory funding requirements. The decline in the global equity
markets that occurred during 2001 contributed significantly to the decrease in
the plan assets. The impact of the negative market returns was attributable to
most of the increase in the unrecognized net actuarial loss since the difference
between the expected return and actual return on plan assets is deferred. The
net actuarial loss for other postretirement benefits of $227.8 million in 2001
resulted primarily from a change in the assumption for future increases in per
capita cost of health care benefits and other changes in actuarial assumptions.
There were no plan assets for the Company's other postretirement benefit
plans at December 31, 2001 and 2000 as postretirement benefits are funded by the
Company when claims are paid. The current portion of the accrued benefit
liability for other postretirement benefits was $85.0 million and $75.0 million
at December 31, 2001 and 2000, respectively.
At December 31, 2001 and 2000, the accumulated benefit obligations, which
represent the obligations of the defined benefit plans if the plans were
terminated and before considering plan assets, were $2,971.8 million and
$2,934.0 million, respectively.
Assumptions used in developing the projected benefit obligations at December
31 were as follows:
[Enlarge/Download Table]
PENSIONS OTHER POSTRETIREMENT BENEFITS
WEIGHTED AVERAGE ASSUMPTIONS ---------------------------- ---------------------------------
AT DECEMBER 31, 2001 2000 1999 2001 2000 1999
-----------------------------------------------------------------------------------------------------------------------------------
Discount rate 7.25% 7.5% 7.75% 7.25% 7.5% 7.75%
Rate of compensation increase 4.0% 4.0% 4.5% -- -- --
Expected return on plan assets 9.25% 9.5% 9.5% -- -- --
Increases in per capita cost of health care benefits
that gradually decreases and is held constant
thereafter beginning in 2005 -- -- -- 9.5%-5.0% 7.0%-5.0% 7.5%-5.0%
The assumed health care cost trend rates have a significant effect on the
amounts reported. A one percentage point increase in the assumed health care
cost trend rates would increase the postretirement benefit obligation by $146.4
million and the total service and interest cost components from continuing
operations by $13.7 million. A one percentage point decrease in the
46 Wyeth and Subsidiaries
assumed health care cost trend rates would decrease the postretirement benefit
obligation by $122.3 million and the total service and interest cost components
from continuing operations by $11.3 million.
Net periodic benefit cost from continuing operations for 2001, 2000 and 1999
of the Company's defined benefit plans (principally U.S. plans) was as follows:
[Enlarge/Download Table]
PENSIONS OTHER POSTRETIREMENT BENEFITS
COMPONENTS OF NET PERIODIC BENEFIT COST ------------------------------------ ------------------------------------
FROM CONTINUING OPERATIONS (In thousands) 2001 2000 1999 2001 2000 1999
-----------------------------------------------------------------------------------------------------------------------------------
Service cost $ 78,634 $ 74,656 $ 69,056 $ 24,179 $ 20,460 $ 23,001
Interest cost 226,786 225,248 211,971 76,966 77,666 74,871
Expected return on plan assets (246,449) (270,131) (260,323) -- -- --
Amortization of prior service cost 11,720 10,704 10,734 2,003 330 339
Amortization of transition obligation 1,999 2,184 1,114 -- -- --
Recognized net actuarial loss 2,250 2,091 2,827 127 134 6,852
Curtailment gain -- -- (1,502) -- -- --
-----------------------------------------------------------------------------
Net periodic benefit cost from continuing operations $ 74,940 $ 44,752 $ 33,877 $ 103,275 $ 98,590 $ 105,063
=============================================================================
Net periodic pension benefit cost from continuing operations was higher in
2001 compared with 2000 due primarily to the decrease in the expected return on
plan assets of the U.S. pension plans. The fair value of the U.S. pension plan
assets between 2000 and 1999 decreased by $270.2 million, which negatively
affected the amount of expected return on plan assets for 2001. Net periodic
pension benefit cost from continuing operations was higher in 2000 compared with
1999 due primarily to consolidating a subsidiary in Japan effective January 1,
2000 (see Note 1).
As a result of the sale of the Cyanamid Agricultural Products business, the
Company realized a curtailment gain related to the pension plans of $25.5
million. This curtailment gain was recorded in Loss on disposal of agricultural
products business.
7. DERIVATIVE INSTRUMENTS AND FOREIGN CURRENCY RISK MANAGEMENT PROGRAMS
As of January 1, 2001, the Company adopted SFAS Nos. 133 and 138, which require
that all derivative financial instruments be measured at fair value and be
recognized as assets or liabilities on the balance sheet with changes in the
fair value of the derivatives recognized in either income (loss) from continuing
operations or accumulated other comprehensive income (loss), depending on the
timing and designated purpose of the derivative. The fair value of forward
contracts and interest rate swaps reflects the present value of the future
potential gain if settlement were to take place on December 31, 2001, with the
fair value of option contracts reflecting the present value of future cash flows
if the contract were settled on December 31, 2001. The impact on the Company's
financial position, results of operations and cash flows, upon adoption of these
pronouncements, was immaterial.
The Company currently engages in two primary programs to manage its exposure
to foreign currency risk. The two programs and the corresponding derivative
contracts outstanding as of December 31, 2001 were as follows:
1. Short-term foreign exchange forward contracts and swap contracts are used to
neutralize month-end balance sheet exposures. These contracts essentially
take the opposite currency position of that projected in the month-end
balance sheet to counterbalance the effect of any currency movement. These
derivative instruments are not designated as hedges and are recorded at fair
value with any gains or losses recognized in current period earnings in
accordance with the requirements of SFAS Nos. 133 and 138. In 2001, the
Company recorded a gain of $28.7 million in Other income, net relating to
gains and losses on these foreign exchange forward contracts and swap
contracts. The $28.7 million consists of gains and losses from contracts
settled during 2001, as well as contracts outstanding at December 31, 2001
that are recorded at fair value.
2. The Company uses foreign currency put options and foreign currency forward
contracts in its cash flow hedging program to cover foreign currency risk
related to international intercompany inventory sales. These instruments are
designated as cash flow hedges, and, in accordance with SFAS Nos. 133 and
138, any unrealized gains or losses are included in accumulated other
comprehensive income (loss) with the corresponding asset or liability
recorded in the balance sheet. As of December 31, 2001, $4.4 million
after-tax of net gains relating to these cash flow hedges was included in
Accumulated other comprehensive loss with the corresponding
assets/liabilities recorded in Other current assets including deferred
taxes/Accrued expenses. The unrealized net gains in Accumulated other
comprehensive loss will be reclassified into the Consolidated Statement of
Operations when the intercompany inventory is sold to a third party. As
such, the Company anticipates recognizing these net gains during the next
six months. Put option contracts outstanding as of December 31, 2001 expire
no later than June 2002.
Occasionally the Company purchases foreign currency put options outside
of the cash flow hedging program to protect additional intercompany
inventory sales. These put
Wyeth and Subsidiaries 47
options do not qualify as cash flow hedges under SFAS Nos. 133 and 138 and
were recorded at fair value with all gains or losses, which were not
significant, recognized in current period earnings immediately.
In addition to the programs identified above, the Company has entered into a
foreign exchange forward contract to hedge against foreign exchange fluctuations
on a yen denominated long-term intercompany loan to the Company's Japanese
subsidiary. The forward contract has been designated as and qualifies for
foreign currency cash flow hedge accounting treatment. As of December 31, 2001,
the Company had recorded gains of $3.5 million after-tax in Accumulated other
comprehensive loss relating to this foreign exchange forward contract.
The Company also has entered into interest rate swaps to manage interest rate
exposures. The Company strives to achieve a desired balance between fixed-rate
and floating-rate debt and has entered into two effective fair value interest
rate swaps on its $1,500.0 million 6.70% Notes to ensure this desired balance
between fixed-rate and floating-rate debt. The interest rate swaps effectively
converted a portion of the Company's fixed-rate debt into floating-rate debt.
Interest expense on the $1,500.0 million 6.70% Notes is adjusted to include the
payments made or received under the interest rate swap agreements. The fair
value of the swaps relating to the $1,500.0 million 6.70% Notes, as of December
31, 2001, excluding accrued interest, was an asset of $12.8 million and has been
recorded in Other assets including deferred taxes with the corresponding
adjustment recorded to the underlying 6.70% Notes in Long-term debt.
8. CAPITAL STOCK
There were 2,400,000,000 shares of common stock and 5,000,000 shares of
preferred stock authorized at December 31, 2001 and 2000. Of the authorized
preferred shares, there is a series of shares (20,486 and 21,948 outstanding at
December 31, 2001 and 2000, respectively) which is designated as $2.00
convertible preferred stock. Each share of the $2.00 series is convertible at
the option of the holder into 36 shares of common stock. This series may be
called for redemption at $60.00 per share plus accrued dividends.
On October 7, 1999, the Company's Board of Directors declared a dividend of
one preferred share purchase right for each share of common stock outstanding on
October 18, 1999. The rights also apply to all future stock issuances. Each
right permits the holder, under certain circumstances and upon the occurrence of
certain events, to purchase from the Company one one-thousandth of a share of
Series A Junior Participating Preferred Stock of the Company (the Series A
Preferred Stock) at an exercise price of $225 per one one-thousandth of a share
of Series A Preferred Stock under a Rights Plan relating to such Series A
Preferred Stock. The 5,000,000 shares of preferred stock authorized will be used
for the exercise of any preferred share purchase rights. The Rights Plan has
provisions that are triggered if any person or group acquires beneficial
ownership of 15% or more of the outstanding common stock or acquires the Company
in a merger or other business combination (an Acquiring Person). In such event,
stockholders (other than the Acquiring Person) would receive stock of the
Company or the Acquiring Person, as the case may be, having a market value of
twice the exercise price along with substantially increased voting and dividend
rights, among other things. The rights expire on October 7, 2009, and prior to
there being an Acquiring Person, the Company may redeem the rights issued under
the Rights Plan for $0.01 per right. The Company can, for so long as the rights
are then redeemable, supplement or amend the Rights Plan in any respect without
the approval of any holders of the rights. At any time after the rights are no
longer redeemable, the Company may supplement or amend the Rights Plan in
certain respects provided that no such supplement or amendment shall adversely
affect the interests of the holders of Rights Certificates as such (other than
an Acquiring Person or an Affiliate or Associate of an Acquiring Person).
Changes in outstanding common shares during 2001, 2000 and 1999 were as
follows:
[Download Table]
(In thousands except shares of
preferred stock) 2001 2000 1999
----------------------------------------------------------------------------
Balance at January 1 1,311,774 1,303,916 1,312,399
Issued for stock options 8,550 15,123 10,589
Purchases of common stock
for treasury -- (7,414) (19,226)
Conversions of preferred stock
(1,462, 2,293 and 1,239
shares in 2001, 2000 and
1999, respectively) and
other exchanges 246 149 154
----------------------------------------
Balance at December 31 1,320,570 1,311,774 1,303,916
========================================
The Company has a common stock repurchase program under which the Company is
authorized to repurchase common shares. At December 31, 2001, the Company was
authorized to repurchase 6,492,460 common shares in the future.
9. STOCK OPTIONS
The Company has one Stock Option Plan and four Stock Incentive Plans. No further
grants may be made under the Stock Option Plan or the Stock Incentive Plan
approved in 1990. Under the Stock Incentive Plans, options to purchase a maximum
of 181,000,000 shares may be granted at prices not less than 100% of the fair
market value of the Company's common stock on the date the option is granted. At
December 31, 2001, there were 19,974,293 shares available for future grants
under the Stock Incentive Plans. In January 2002, the Board of Directors
adopted, subject to stockholder approval at the Company's annual meeting on
April 25, 2002, the 2002 Stock Incentive Plan under which 65,000,000 shares are
available for future grants.
48 Wyeth and Subsidiaries
The plans provide for the granting of incentive stock options as defined
under the Internal Revenue Code. Under the plans, grants may be made to selected
officers and employees of non-qualified stock options with a 10-year term or
incentive stock options with a term not exceeding 10 years. The plans also
provide for the granting of stock appreciation rights (SAR), which entitle the
holder to receive shares of the Company's common stock or cash equal to the
excess of the market price of the common stock over the exercise price when
exercised. At December 31, 2001, there were no outstanding SARs.
Each Stock Incentive Plan allows for, among other things, the issuance of up
to 8,000,000 shares (24,000,000 shares in the aggregate for all Stock Incentive
Plans) as restricted stock awards. Restricted stock awards representing 290,995,
148,900 and 148,850 units were granted in 2001, 2000 and 1999, respectively,
under the plans to certain employees, including key executives. Most of these
units are converted to shares of restricted stock based on the achievement of
certain performance criteria related to performance years 1999 through 2005. The
remaining units are converted generally at the end of four years.
Under the Stock Option Plan for Non-Employee Directors, a maximum of 250,000
shares may be granted to non-employee directors at 100% of the fair market value
of the Company's common stock on the date of the grant. Stock options granted to
non-employee directors were 36,000, 21,000 and 21,000 in 2001, 2000 and 1999,
respectively. Shares available for future grants at December 31, 2001 were
172,000.
Under the 1994 Restricted Stock Plan for Non-Employee Directors, a maximum of
100,000 restricted shares may be granted to non-employee directors. The
restricted shares granted to each non-employee director are not delivered prior
to the end of a five-year restricted period. At December 31, 2001, 64,800 shares
were available for future grants.
Stock option information related to the plans was as follows:
[Enlarge/Download Table]
WEIGHTED Weighted Weighted
AVERAGE Average Average
EXERCISE Exercise Exercise
STOCK OPTIONS 2001 PRICE 2000 Price 1999 Price
-------------------------------------------------------------------------------------------------------------------------------
Outstanding at January 1 82,751,313 $43.74 85,244,130 $39.13 75,790,629 $30.53
Granted 28,360,196 56.89 16,496,678 56.51 21,945,755 62.00
Canceled (2,558,655) 57.36 (3,866,134) 58.32 (1,903,601) 51.83
Exercised (2001 --
$14.52 to $62.31 per share) (8,549,782) 26.74 (15,123,361) 27.90 (10,588,653) 22.76
----------- ---------- ----------
Outstanding at December 31
(2001 -- $14.52 to
$65.19 per share) 100,003,072 48.57 82,751,313 43.74 85,244,130 39.13
----------- ---------- ----------
Exercisable at December 31 57,205,798 41.93 51,830,094 35.31 52,789,450 28.27
----------- ---------- ----------
The following table summarizes information regarding stock options
outstanding at December 31, 2001:
[Enlarge/Download Table]
OPTIONS OUTSTANDING OPTIONS EXERCISABLE
-------------------------------------------------------------------------------------- -------------------------------------
WEIGHTED AVERAGE WEIGHTED AVERAGE WEIGHTED AVERAGE
RANGE OF NUMBER REMAINING EXERCISE NUMBER EXERCISE
EXERCISE PRICES OUTSTANDING CONTRACTUAL LIFE PRICE EXERCISABLE PRICE
----------------------------------------------------------------------------------------------------------------------------------
$14.52 to 19.99 11,672,218 2.4 years $17.90 11,672,218 $17.90
20.00 to 29.99 4,253,391 3.9 years 26.34 4,253,391 26.34
30.00 to 39.99 12,442,005 4.8 years 36.18 12,442,005 36.18
40.00 to 49.99 624,588 7.1 years 45.93 446,583 46.22
50.00 to 59.99 52,067,568 8.4 years 55.25 16,380,958 52.38
60.00 to 65.19 18,943,302 7.6 years 62.30 12,010,643 62.33
----------- ----------
100,003,072 6.9 years 48.57 57,205,798 41.93
=========== ==========
The Company accounts for stock-based compensation using the intrinsic value
method. Accordingly, no compensation expense has been recognized for stock
options. If compensation expense for the Company's stock options issued in 2001,
2000
Wyeth and Subsidiaries 49
and 1999 had been determined based on the fair value method of accounting, the
Company's net income (loss) and earnings (loss) per share would have been
adjusted to the pro forma amounts indicated below:
[Download Table]
(In thousands except
per share amounts) 2001 2000 1999
-----------------------------------------------------------------------------------
Net income (loss)
less preferred
dividends:
As-reported $ 2,285,252 $ (2,370,733) $ (1,227,171)
Pro forma 2,084,564 (2,520,657) (1,312,238)
Basic earnings
(loss) per share:
As-reported $ 1.74 $ (1.81) $ (0.94)
Pro forma 1.58 (1.93) (1.00)
Net income (loss):
As-reported $ 2,285,294 $ (2,370,687) $ (1,227,121)
Pro forma 2,084,606 (2,520,611) (1,312,188)
Diluted earnings
(loss) per share*:
As-reported $ 1.72 $ (1.81) $ (0.94)
Pro forma 1.57 (1.93) (1.00)
* The total weighted average common shares outstanding for diluted loss per
share for 2000 and 1999 did not include common stock equivalents, as the effect
would have been antidilutive.
The fair value of issued stock options is estimated on the date of grant
using a variant of the Black-Scholes option pricing model incorporating the
following assumptions for stock options granted in 2001, 2000 and 1999,
respectively: expected volatility (the amount by which the stock price is
expected to fluctuate) of 32.1%, 31.2% and 25.0%; expected dividend yield of
1.6%, 1.6% and 2.2%; risk-free interest rate of 4.8%, 6.3% and 5.6%; and
expected life of five, five and four years. The weighted average fair value of
stock options granted during 2001, 2000 and 1999 was $17.76, $18.76 and $14.36
per option share, respectively.
10. ACCUMULATED OTHER COMPREHENSIVE LOSS
Accumulated other comprehensive loss consists of changes in foreign currency
translation adjustments, net unrealized gains on derivative contracts and net
unrealized gains (losses) on marketable securities. The following table sets
forth the changes in each component of Accumulated other comprehensive loss:
[Enlarge/Download Table]
FOREIGN NET UNREALIZED NET UNREALIZED ACCUMULATED
CURRENCY GAINS ON GAINS (LOSSES) ON OTHER
TRANSLATION DERIVATIVE MARKETABLE COMPREHENSIVE
(In thousands) ADJUSTMENTS(1) CONTRACTS(2) SECURITIES LOSS
------------------------------------------------------------------------------------------------------------------
Balance January 1, 1999 $(329,004) -- $ 667 $(328,337)
Period change (285,963) -- 815 (285,148)
--------------------------------------------------------------------------
Balance December 31, 1999 (614,967) -- 1,482 (613,485)
Period change (70,496) -- 11,422 (59,074)
--------------------------------------------------------------------------
Balance December 31, 2000 (685,463) -- 12,904 (672,559)
Period change (166,200) $7,865 (2,134) (160,469)
--------------------------------------------------------------------------
Balance December 31, 2001 $(851,663) $7,865 $10,770 $(833,028)
==========================================================================
(1) Income taxes are generally not provided for foreign currency translation
adjustments, as such adjustments relate to permanent investments in
international subsidiaries.
(2) Deferred income tax provided for net unrealized gains on derivative
contracts in 2001 was $1,000.
11. INCOME TAXES
The provision (benefit) for federal and foreign income taxes from continuing
operations consisted of:
[Download Table]
(In thousands)
YEARS ENDED DECEMBER 31, 2001 2000 1999
-----------------------------------------------------------------
Current:
Federal $(96,805) $ 321,484 $ 290,020
Foreign 412,438 292,798 419,992
-----------------------------------
315,633 614,282 710,012
Deferred:
Federal 270,144 (836,883) (1,399,709)
Foreign (2,324) 22,601 (10,359)
-----------------------------------
267,820 (814,282) (1,410,068)
-----------------------------------
$583,453 $(200,000) $ (700,056)
===================================
Net deferred tax assets inclusive of valuation allowances for certain
deferred tax assets were reflected on the Consolidated Balance Sheets at
December 31 as follows:
[Download Table]
(In thousands) 2001 2000
----------------------------------------------------------------
Net current deferred tax assets $1,526,690 $2,595,662
Net noncurrent deferred tax assets 1,583,599 795,441
-----------------------
Net deferred tax assets $3,110,289 $3,391,103
=======================
Deferred income taxes are provided for temporary differences between the
financial reporting basis and the tax basis of the Company's assets and
liabilities. Deferred tax assets result principally from the recording of
certain accruals and reserves, which currently are not deductible for tax
purposes, as well as net operating loss carryforwards generated primarily from
deductible payments associated with the REDUX and PONDIMIN diet drug
50 Wyeth and Subsidiaries
litigation. Deferred tax liabilities result principally from tax on earnings
expected to be remitted to the United States and the use of accelerated
depreciation for tax purposes.
The components of the Company's deferred tax assets and liabilities at
December 31 were as follows:
[Download Table]
(In thousands) 2001 2000
-----------------------------------------------------------------------
Deferred tax assets:
Diet drug product litigation accruals $ 650,192 $ 2,857,951
Product litigation and environmental
liabilities and other accruals 660,282 760,827
Postretirement, pension and other
employee benefits 536,676 592,709
Net operating loss and other tax
credit carryforwards 1,756,522 4,134
Goodwill impairment 52,837 60,000
Restructuring and product
discontinuations 113,638 129,143
Inventory reserves 127,175 94,393
Investments and advances 31,869 38,894
Research and development costs 554,521 --
Intangibles 58,538 51,568
Other 40,375 63,437
---------------------------
Total deferred tax assets 4,582,625 4,653,056
---------------------------
Deferred tax liabilities:
Tax on earnings expected to be
remitted to the United States (700,000) (700,000)
Depreciation (370,916) (277,512)
Pension benefits and other
employee benefits (140,004) (54,751)
Equity investments (110,204) (102,945)
Other (101,630) (75,592)
---------------------------
Total deferred tax liabilities (1,422,754) (1,210,800)
---------------------------
Deferred tax asset valuation allowances (49,582) (51,153)
---------------------------
Net deferred tax assets $ 3,110,289 $ 3,391,103
===========================
Valuation allowances have been established for certain deferred tax assets
related to environmental liabilities and other operating accruals as the Company
determined that it was more likely than not that these benefits will not be
realized. During 2001 and 2000, the valuation allowance decreased by $1.6
million and $100.3 million, respectively. The decrease of the valuation
allowance in 2000 related to a reduction in net operating loss carryforwards as
a result of the deconsolidation of Immunex (see Note 2).
The Company has provided $700.0 million of federal income taxes on unremitted
earnings from its international subsidiaries that may be remitted back to the
United States. Federal income taxes were not provided on unremitted earnings
expected to be permanently reinvested internationally. If federal income taxes
were provided, they would approximate $380.0 million.
Reconciliations between the Company's effective tax rate and the U.S.
statutory rate from continuing operations, excluding the diet drug litigation
charges in 2001, 2000 and 1999 (see Note 12), the effect of the termination fee
in 2000 (see Note 3), gain on the sale of Immunex common stock in 2000 (see Note
2), goodwill impairment in 2000 (see Note 3) and special charges in 2000 and
1999 (see Note 3), were as follows:
[Download Table]
TAX RATE
YEARS ENDED DECEMBER 31, 2001 2000 1999
------------------------------------------------------------
U.S. statutory rate 35.0% 35.0% 35.0%
Effect of Puerto Rico and Ireland
manufacturing operations (9.1) (8.6) (9.0)
Research credits (2.1) (1.7) (1.4)
Goodwill amortization 1.2 1.5 1.8
Other, net (0.9) (0.7) 0.7
----- ----- -----
Effective tax rate from
continuing operations 24.1% 25.5% 27.1%
===== ===== =====
Including the effect of the 2001 litigation charge (which had a 35.3% tax
benefit), the overall effective tax rate from continuing operations in 2001 was
20.3%. Including the effect of the termination fee and the gain on the sale of
Immunex common stock in 2000 (which had tax provisions of 35.0% and 31.4%,
respectively), and the tax benefits associated with the 2000 litigation charge,
goodwill impairment and special charges (with effective rates of 28.3%, 15.0%
and 35.2%, respectively), the overall effective tax rate from continuing
operations in 2000 was an 18.2% tax benefit. Including the effect of the 1999
litigation charge and special charge (which had 30.8% and 35.4% of tax benefits,
respectively), the overall effective tax rate from continuing operations in 1999
was a 36.7% tax benefit. The difference in the tax benefits related to the 2000
and 1999 litigation charges versus the statutory rate of 35.0% was caused by
provisions of $500.0 million and $200.0 million in 2000 and 1999, respectively,
for additional federal income taxes, net of tax credits, that may be paid if the
Company remits certain international earnings, taxed at a lower rate than in the
United States, to the United States for diet drug litigation settlement
payments.
Total income tax payments, net of tax refunds, for continuing and
discontinued operations in 2001, 2000 and 1999 amounted to $493.6 million,
$1,038.3 million and $717.2 million, respectively.
12. CONTINGENCIES AND LITIGATION CHARGES
The Company is involved in various legal proceedings, including product
liability and environmental matters of a nature considered normal to its
business (see Note 5 for discussion of environmental matters). It is the
Company's policy to accrue for amounts related to these legal matters if it is
probable that a liability has been incurred and an amount is reasonably
estimable.
The Company has been named as a defendant in numerous legal actions relating
to the diet drugs REDUX or PONDIMIN, which the Company estimated were used in
the United States, prior to their 1997 voluntary market withdrawal, by
Wyeth and Subsidiaries 51
approximately 5.8 million people. These actions allege, among other things, that
the use of REDUX and/or PONDIMIN, independently or in combination with the
prescription drug phentermine (which the Company did not manufacture, distribute
or market), caused certain serious conditions, including valvular heart disease.
On October 7, 1999, the Company announced a nationwide, class action
settlement (the settlement) to resolve litigation brought against the Company
regarding the use of the diet drugs REDUX or PONDIMIN. The settlement covers all
claims arising out of the use of REDUX or PONDIMIN, except for claims of primary
pulmonary hypertension (PPH), and is open to all REDUX or PONDIMIN users in the
United States, regardless of whether they have lawsuits pending.
On November 23, 1999, U.S. District Judge Louis C. Bechtle granted
preliminary approval of the settlement and directed that notice of the
settlement terms be provided to class members. The notice program began in
December 1999. In early May 2000, the district court held a hearing on the
fairness of the terms of the settlement, with an additional one-day hearing on
August 10, 2000. On August 28, 2000, Judge Bechtle issued an order approving the
settlement. Several appeals were taken from that order to the U.S. Court of
Appeals for the Third Circuit. All but one of those appeals was withdrawn during
2001, and, on August 15, 2001, the Third Circuit affirmed the approval of the
settlement. When no petitions to the U.S. Supreme Court for certiorari were
filed by January 2, 2002, the settlement was deemed to have received final
judicial approval on January 3, 2002.
Payments by the Company related to the settlement are made into settlement
Funds A and B (the settlement funds). Fund A is intended to cover refunds,
medical screening costs, additional medical services and cash payments,
education and research costs, and administration costs. Fund B will compensate
claimants with significant heart valve disease. Payments to provide settlement
benefits, if needed, may continue for approximately 16 years after final
judicial approval. Payments to the settlement funds in 2001, 2000 and 1999 were
$936.7 million, $383.0 million and $75.0 million, respectively.
Diet drug users choosing to opt out of the settlement class were required to
do so by March 30, 2000. The Company has resolved the claims of the majority of
these initial opt outs and continues to resolve the claims of the remaining
individuals.
The settlement agreement also gives class members who participate in the
settlement the opportunity to opt out of the settlement at two later stages,
although there are restrictions on the nature of claims they can pursue outside
of the settlement. Class members who are diagnosed with certain levels of
valvular regurgitation within a specified time frame can opt out following their
diagnosis and prior to receiving any further benefits under the settlement
(intermediate opt outs). Class members who are diagnosed with certain levels of
regurgitation and who elect to remain in the settlement, but who later develop a
more severe valvular condition, may opt out at the time the more serious
condition develops (back-end opt outs). Under either of these latter two opt out
alternatives, class members may not seek or recover punitive damages, may sue
only for the condition giving rise to the opt out right, and may not rely on
verdicts, judgments or factual findings made in other lawsuits.
On January 18, 2002, as collateral for the Company's financial obligations
under the settlement, the Company established a security fund in the amount of
$370.0 million and recorded such amount in Other assets including deferred
taxes. The funds are owned by the Company and will earn interest income for the
Company while residing in the security fund. The Company will be required to
deposit an additional $180.0 million in the security fund if the Company's
credit rating, as reported by both Moody's and S&P, falls below investment
grade.
The Company recorded an initial litigation charge of $4,750.0 million
($3,287.5 million after-tax or $2.51 per share-diluted), net of insurance, in
connection with the REDUX and PONDIMIN litigation in 1999, an additional charge
of $7,500.0 million in 2000 ($5,375.0 million after-tax or $4.11 per
share-diluted), and a third litigation charge of $950.0 million ($615.0 million
after-tax or $0.46 per share-diluted) in the 2001 third quarter. The combination
of these three charges represents the estimated total amount required to resolve
all diet drug litigation, including anticipated funding requirements for the
nationwide, class action settlement, anticipated costs to resolve the claims of
any members of the settlement class who in the future may exercise an
intermediate or back-end opt out right, costs to resolve the claims of PPH
claimants and initial opt out claimants, and administrative and litigation
expenses.
At December 31, 2001, $1,857.7 million of the litigation accrual remained;
$1,150.0 million and $707.7 million were included in Accrued expenses and Other
noncurrent liabilities, respectively. At December 31, 2000, $8,165.6 million of
the litigation accrual remained; $5,900.0 million and $2,265.6 million were
included in Accrued expenses and Other noncurrent liabilities, respectively.
Payments to the nationwide, class action settlement funds, individual settlement
payments, legal fees and other items were $7,257.9 million, $3,966.8 million and
$117.6 million for 2001, 2000 and 1999, respectively.
The Company is self-insured against ordinary product liability risks and has
liability coverage, in excess of certain limits and subject to certain policy
ceilings, from various insurance carriers.
In the opinion of the Company, although the outcome of any legal proceedings
cannot be predicted with certainty, the ultimate liability of the Company in
connection with its legal proceedings will not have a material adverse effect on
the Company's financial position but could be material to the results of
operations and cash flows in any one accounting period.
52 Wyeth and Subsidiaries
The Company leases certain property and equipment for varying periods under
operating leases. Future minimum rental payments under non-cancelable operating
leases from continuing operations with terms in excess of one year in effect at
December 31, 2001 are as follows:
[Download Table]
(In thousands)
----------------------------------------------------------------
2002 $ 80,845
2003 74,312
2004 55,546
2005 50,214
2006 46,687
Thereafter 35,289
--------
Total rental commitments $342,893
========
Rental expense from continuing operations for all operating leases was $133.7
million, $128.2 million and $135.1 million in 2001, 2000 and 1999, respectively.
13. COMPANY DATA BY OPERATING AND GEOGRAPHIC SEGMENT
The Company has three reportable segments: Pharmaceuticals, Consumer Health Care
and Corporate. The Company's Pharmaceuticals and Consumer Health Care reportable
segments are strategic business units that offer different products and
services. The reportable segments are managed separately because they
manufacture, distribute and sell distinct products and provide services, which
require various technologies and marketing strategies. The Company is not
dependent on any single customer or major group of customers for its net revenue
(see Note 1).
The Pharmaceuticals segment manufactures, distributes and sells branded and
generic human ethical pharmaceuticals, biologicals, nutritionals, and animal
biologicals and pharmaceuticals. Principal products include women's health care
products, neuroscience therapies, cardiovascular products, infant nutritionals,
gastroenterology drugs, anti-infectives, vaccines, biopharmaceuticals, oncology
therapies, musculoskeletal therapies, hemophilia treatments and immunological
products. Principal animal health products include vaccines, pharmaceuticals,
endectocides and growth implants.
The Consumer Health Care segment manufactures, distributes and sells
over-the-counter health care products whose principal products include
analgesics, cough/cold/allergy remedies, nutritional supplements, herbal
products, and hemorrhoidal, antacid, asthma and other relief items.
Corporate is responsible for the treasury, tax and legal operations of the
Company's businesses and maintains and/or incurs certain assets, liabilities,
expenses, gains and losses related to the overall management of the Company
which are not allocated to the other reportable segments.
The accounting policies of the segments described above are the same as those
described in "Summary of Significant Accounting Policies" in Note 1. The Company
evaluates the performance of the Pharmaceuticals and Consumer Health Care
reportable segments based on income from continuing operations before taxes
which includes goodwill amortization, gains on the sales of non-corporate assets
and certain other items. Corporate includes special charges, interest expense
and interest income, gains on the sales of investments and other corporate
assets, including the sale of Immunex common stock, the Warner-Lambert Company
termination fee, certain litigation provisions, including the REDUX and PONDIMIN
litigation charges, goodwill impairment and other miscellaneous items.
COMPANY DATA BY OPERATING SEGMENT
[Download Table]
(In millions)
YEARS ENDED DECEMBER 31, 2001 2000 1999
---------------------------------------------------------------------
NET REVENUE FROM
CUSTOMERS(1)
Pharmaceuticals $ 11,716.5 $ 10,772.6 $ 9,469.7
Consumer Health Care 2,412.0 2,441.1 2,345.4
---------------------------------------
Consolidated Total $ 14,128.5 $ 13,213.7 $ 11,815.1
=======================================
INCOME (LOSS) FROM
CONTINUING
OPERATIONS BEFORE
TAXES(2)
Pharmaceuticals $ 3,503.5 $ 2,919.5 $ 2,538.6
Consumer Health Care 592.1 626.6 594.6
Corporate(3) (1,226.9) (4,647.1) (5,040.5)
---------------------------------------
Consolidated Total $ 2,868.7 $ (1,101.0) $ (1,907.3)
=======================================
DEPRECIATION AND
AMORTIZATION EXPENSE
Pharmaceuticals $ 539.1 $ 458.8 $ 465.6
Consumer Health Care 53.1 61.0 57.3
Corporate 15.5 15.2 18.3
---------------------------------------
Consolidated Total $ 607.7 $ 535.0 $ 541.2
=======================================
EXPENDITURES FOR
LONG-LIVED ASSETS
Pharmaceuticals $ 1,827.7 $ 1,720.1 $ 1,038.9
Consumer Health Care 67.8 38.4 66.8
Corporate 178.0 55.0 31.4
---------------------------------------
Consolidated Total $ 2,073.5 $ 1,813.5 $ 1,137.1
=======================================
TOTAL ASSETS
AT DECEMBER 31,
Pharmaceuticals(4) $ 13,820.3 $ 12,388.6 $ 11,101.4
Consumer Health Care 1,736.3 1,697.2 1,864.4
Net assets -- discontinued
business held for sale -- -- 4,192.3
Corporate 7,411.3 7,006.7 5,965.7
---------------------------------------
Consolidated Total $ 22,967.9 $ 21,092.5 $ 23,123.8
=======================================
Wyeth and Subsidiaries 53
COMPANY DATA BY GEOGRAPHIC SEGMENT
[Download Table]
(In millions)
YEARS ENDED DECEMBER 31, 2001 2000 1999
------------------------------------------------------------------
NET REVENUE FROM
CUSTOMERS(1)(5)
United States $ 9,029.0 $ 8,045.1 $ 7,214.2
United Kingdom 694.4 898.1 745.1
Other International 4,405.1 4,270.5 3,855.8
-----------------------------------
Consolidated Total $14,128.5 $13,213.7 $11,815.1
===================================
LONG-LIVED ASSETS
AT DECEMBER 31,(5)
United States $ 7,583.4 $ 6,228.8 $ 6,379.7
Ireland 652.7 386.2 326.8
Other International 2,482.6 2,688.6 2,498.0
-----------------------------------
Consolidated Total $10,718.7 $ 9,303.6 $ 9,204.5
===================================
-----------
(1) 2000 and 1999 were restated to reflect the early adoption of new
authoritative accounting guidance as of January 1, 2001 reflecting certain
rebates and sales incentives (i.e., coupons and other rebate programs) as
reductions of revenues instead of selling and marketing expenses.
(2) Income (loss) from continuing operations before taxes included goodwill
amortization for 2001, 2000 and 1999 as follows: Pharmaceuticals -- $136.8,
$147.8 and $154.3 and Consumer Health Care -- $23.7, $31.8 and $32.7,
respectively.
(3) 2001, 2000 and 1999 Corporate included litigation charges of $950.0,
$7,500.0 and $4,750.0, respectively, relating to the litigation brought
against the Company regarding the use of the diet drug products REDUX or
PONDIMIN. The charges provide for all anticipated payments in connection
with the nationwide, class action settlement, anticipated costs to resolve
the claims of any members of the settlement class who in the future may
exercise an intermediate or back-end opt out right, costs to resolve the
claims of PPH claimants and initial opt out claimants, and administrative
and litigation expenses, net of insurance (see Note 12). The charges
related to the Pharmaceuticals operating segment.
2000 Corporate also included:
- Income of $1,709.4 resulting from the receipt of a $1,800.0
termination fee provided for under the merger agreement with
Warner-Lambert Company offset, in part, by certain related expenses
(see Note 3).
- Income of $2,061.2 relating to the Company selling a portion of its
investment in Immunex common stock in a public equity offering with
Immunex (see Note 2). The transaction related to the Pharmaceuticals
operating segment.
- Goodwill impairment of $401.0 related to the goodwill associated with
generic pharmaceuticals and the SOlGAR consumer health care product
line. The charge related to the operating segments as follows:
Pharmaceuticals -- $231.0 and Consumer Health Care -- $170.0 (see Note
3).
- A special charge of $80.0 related to the voluntary ceasing of
production and subsequent market withdrawal of products containing PPA
(see Note 3). The charge related to the Consumer Health Care operating
segment.
- A special charge of $267.0 related to costs associated with certain
product discontinuations (see Note 3). The charge related to the
Pharmaceuticals operating segment.
1999 Corporate also included a special charge of $82.0 related to the
suspension of shipments and the voluntary market withdrawal of ROTASHIELD,
the Company's rotavirus vaccine (see Note 3). The charge related to the
Pharmaceuticals operating segment.
(4) 2001 and 2000 included an equity investment in Immunex of $845.4 and
$759.2, respectively. Immunex was a consolidated subsidiary in 1999.
(5) Other than the United States and the United Kingdom, no other country in
which the Company operates had net revenue of 5% or more of the respective
consolidated total. Other than the United States and Ireland, no country in
which the Company operates had long-lived assets of 5% or more of the
respective consolidated total. The basis for attributing net revenue to
geographic areas is the location of the customer. Long-lived assets consist
of property, plant and equipment, goodwill and other intangibles, and other
assets, excluding deferred taxes, net investments in equity companies and
other investments.
54 Wyeth and Subsidiaries
REPORT OF INDEPENDENT PUBLIC ACCOUNTANTS
To the Board of Directors and Stockholders of Wyeth:
We have audited the accompanying consolidated balance sheets of Wyeth
(formerly American Home Products Corporation -- a Delaware corporation) and
subsidiaries as of December 31, 2001 and 2000, and the related consolidated
statements of operations, changes in stockholders' equity and cash flows for
each of the three years in the period ended December 31, 2001. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with auditing standards generally
accepted in the United States. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements. An
audit also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Wyeth and subsidiaries as of
December 31, 2001 and 2000, and the results of their operations and cash flows
for each of the three years in the period ended December 31, 2001 in conformity
with accounting principles generally accepted in the United States.
Arthur Andersen LLP
New York, New York
January 24, 2002
MANAGEMENT REPORT ON FINANCIAL STATEMENTS
Management has prepared and is responsible for the Company's Consolidated
Financial Statements and related Notes to Consolidated Financial Statements.
They have been prepared in accordance with accounting principles generally
accepted in the United States and necessarily include amounts based on judgments
and estimates made by management. All financial information in this Annual
Report is consistent with the financial statements.
The Company maintains internal accounting control systems and related
policies and procedures designed to provide reasonable assurance that assets are
safeguarded, that transactions are executed in accordance with management's
authorization and are properly recorded, and that accounting records may be
relied upon for the preparation of financial statements and other financial
information. The design, monitoring and revision of internal accounting control
systems involve, among other things, management's judgment with respect to the
relative cost and expected benefits of specific control measures. The Company
also maintains an internal auditing function, which evaluates and formally
reports on the adequacy and effectiveness of internal accounting controls,
policies and procedures.
The Company's financial statements have been audited by independent public
accountants who have expressed their opinion with respect to the fairness of
these statements.
The Audit Committee of the Board of Directors, composed of non-employee
directors, meets periodically with the independent public accountants and
internal auditors to evaluate the effectiveness of the work performed by them in
discharging their respective responsibilities and to assure their independent
and free access to the Committee.
John R. Stafford Robert Essner Kenneth J. Martin
Chairman of the Board President and Senior Vice President
Chief Executive and Chief Financial
Officer Officer
Wyeth and Subsidiaries 55
QUARTERLY FINANCIAL DATA (UNAUDITED)
[Enlarge/Download Table]
FIRST QUARTER SECOND QUARTER THIRD QUARTER FOURTH QUARTER
(IN THOUSANDS EXCEPT PER SHARE AMOUNTS) 2001 2001 2001 2001
------------------------------------------------------------------------------------------------------------------------------------
Net revenue $3,449,176 $3,216,420 $3,736,250 $ 3,726,668
Gross profit 2,650,573 2,425,379 2,856,328 2,807,458
Income from continuing operations(1) 733,554 476,996 252,072 822,672
Diluted earnings per share from continuing operations(1) 0.55 0.36 0.19 0.62
Net income(1) 733,554 476,996 252,072 822,672
[Enlarge/Download Table]
FIRST QUARTER SECOND QUARTER THIRD QUARTER FOURTH QUARTER
(IN THOUSANDS EXCEPT PER SHARE AMOUNTS) 2000 2000 2000 2000
------------------------------------------------------------------------------------------------------------------------------------
Net revenue(2) $3,195,852 $3,026,215 $3,503,605 $ 3,487,999
Gross profit(2) 2,413,860 2,255,173 2,658,346 2,616,874
Income (loss) from continuing operations(1)(3) 1,746,009 412,734 762,100 (3,821,883)
Diluted earnings (loss) per share from continuing operations(1)(3)(4) 1.32 0.31 0.58 (2.91)
Net income (loss)(1)(3)(5) 276,362 412,734 762,100 (3,821,883)
(1) Third Quarter 2001 and Fourth Quarter 2000 included litigation charges of
$615,000 after-tax and $0.46 per share-diluted and $5,375,000 after-tax
and $4.10 per share-diluted, respectively, in connection with litigation
brought against the Company regarding the use of the diet drugs REDUX or
PONDIMIN.
Fourth Quarter 2000 also included:
- Income of $1,414,859 after-tax and $1.08 per share-diluted
related to the Company selling a portion of its investment in
Immunex common stock in a public equity offering with Immunex.
- Goodwill impairment of $341,000 after-tax and $0.26 per
share-diluted related to the goodwill associated with generic
pharmaceuticals and the SOLGAR consumer health care product
line.
- A special charge of $52,000 after-tax and $0.04 per
share-diluted related to the voluntary ceasing of production
and subsequent voluntary market withdrawal of products
containing PPA.
- A special charge of $173,000 after-tax and $0.13 per
share-diluted related to costs associated with certain product
discontinuations.
(2) First, Second, Third and Fourth Quarters 2000 were restated to reflect the
early adoption of new authoritative accounting guidance as of January 1,
2001 reflecting certain rebates and sales incentives (i.e., coupons and
other rebate programs) as reductions of revenues instead of selling and
marketing expenses.
(3) First Quarter 2000 included income of $1,111,097 after-tax and $0.84 per
share-diluted resulting from the receipt of a $1,800,000 termination fee
provided for under the merger agreement with Warner-Lambert Company
offset, in part, by certain related expenses.
(4) The weighted average common shares outstanding for diluted loss per share
for the Fourth Quarter 2000 did not include common stock equivalents, as
the effect would have been antidilutive. In addition, the sum of the 2000
diluted earnings (loss) per share from continuing operations did not equal
the full year 2000 diluted loss per share from continuing operations for
the same reason.
(5) As of the 2000 First Quarter, the Company reflected the Cyanamid
Agricultural Products business, which was sold on June 30, 2000, as a
discontinued operation and recorded a loss on disposal of such business of
$1,572,993, net of tax charges of $855,248.
MARKET PRICES OF COMMON STOCK AND DIVIDENDS
[Enlarge/Download Table]
2001 RANGE OF PRICES* 2000 Range of Prices*
----------------------------------------- -----------------------------------------
DIVIDENDS Dividends
HIGH LOW PER SHARE High Low per Share
--------------------------------------------------------------------------------------------------------------------
First quarter $62.50 $52.00 $0.23 $56.25 $39.38 $0.23
Second quarter 63.80 54.06 0.23 61.63 50.94 0.23
Third quarter 62.31 53.20 0.23 60.13 50.38 0.23
Fourth quarter 62.25 55.70 0.23 65.25 53.50 0.23
* Prices are those of the New York Stock Exchange--Composite Transactions.
56 Wyeth and Subsidiaries
MANAGEMENT'S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following commentary should be read in conjunction with the Consolidated
Financial Statements and Notes to Consolidated Financial Statements on pages 34
to 54.
RESULTS OF OPERATIONS
Basis of Presentation
Management's discussion and analysis of results of operations for 2001 vs. 2000
and 2000 vs. 1999 are presented on an as-reported basis, except for Net revenue
variation explanations between 2000 and 1999, which are presented on an
as-reported and pro forma basis. Effective January 1, 2000, the financial
results of certain pharmaceutical subsidiaries in Japan and India, which
previously were included on an equity basis, were consolidated in the financial
results of the Company. The financial results of Immunex, which previously were
consolidated in the financial results of the Company, were deconsolidated and
included on an equity basis, retroactive to January 1, 2000, within the
pharmaceuticals segment. Accordingly, alliance revenue was recorded in 2001 and
2000 for co-promotion agreements between the Company and Immunex. The 2000 vs.
1999 pro forma net revenue percentage changes reflect the respective
consolidation and deconsolidation of these subsidiaries and include alliance
revenue from Immunex, assuming all transactions occurred as of January 1, 1999.
Neither the consolidation nor the deconsolidation of these subsidiaries had any
effect on income from continuing operations in 2000.
In addition, the Company early adopted new authoritative accounting guidance
as of January 1, 2001 reflecting certain rebates and sales incentives (i.e.,
coupons and other rebate programs) as reductions of revenues instead of selling
and marketing expenses. Financial information for all prior periods presented
has been reclassified to comply with the income statement classification
requirements of the new guidance. These reclassifications had no effect on total
net revenue growth between the periods presented. However, consumer health care
net revenue growth for 2000 vs. 1999 was 3% without the reclassification
adjustments as compared with the as-reported growth rate of 4%.
Net Revenue
Worldwide net revenue increased 7% to $14.1 billion for 2001 on an as-reported
basis. Worldwide net revenue increased 12% to $13.2 billion for 2000 on an
as-reported basis. After adjusting for the consolidation and deconsolidation of
the subsidiaries identified above, and including alliance revenue from Immunex,
pro forma worldwide net revenue for 2000 increased 13% due primarily to higher
worldwide sales of pharmaceuticals.
The following table sets forth 2001, 2000 and 1999 worldwide net revenue
results by operating segment together with the percentage changes in
"As-Reported" and "Pro Forma" (where applicable) worldwide net revenue from
prior years:
[Enlarge/Download Table]
2001 VS. 2000 2000 vs. 1999
------------- ------------------------------
(Dollar amounts in millions) YEARS ENDED DECEMBER 31, As-Reported
-------------------------------------------- % Increase As-Reported Pro Forma
NET REVENUE 2001 2000 1999 (Decrease) % Increase % Increase
----------------------------------------------------------------------------------------------------------------------------------
Operating Segment:
Pharmaceuticals $11,716.5 $10,772.6 $ 9,469.7 9% 14% 16%
Consumer Health Care 2,412.0 2,441.1 2,345.4 (1)% 4% 4%
---------------------------------------------------------------------------------------------------
Consolidated Net Revenue $14,128.5 $13,213.7 $11,815.1 7% 12% 13%
===================================================================================================
2001 VS. 2000
Worldwide pharmaceutical net revenue increased 9% (10% for human
pharmaceuticals) for 2001. Excluding the negative impact of foreign exchange,
worldwide pharmaceutical net revenue increased 11% for 2001. U.S. pharmaceutical
net revenue increased 15% for 2001 due primarily to higher sales of PROTONIX
(introduced in the 2000 second quarter), PREVNAR (introduced in the 2000 first
quarter), EFFEXOR XR (as a result of higher volume and market share of new
prescriptions as well as expanded indications), PREMARIN products and CORDARONE
I.V., and alliance revenue offset, in part, by lower sales of ZIAC (due to
generic competition) and generic products (discontinuance of certain oral
generics).
International pharmaceutical net revenue decreased 1% for 2001 due primarily
to lower sales of MENINGITEC and animal health products offset, in part, by
higher sales of EFFEXOR XR (as a result of higher volume and market share of new
prescriptions, as well as expanded indications), ENBREL (internationally the
Company has exclusive marketing rights to ENBREL), ZOTON and infant
nutritionals. Sales of MENINGITEC, the Company's meningococcal meningitis
vaccine, decreased as compared with the prior year, as it was used in 2000 to
vaccinate nearly all children and adolescents in the United Kingdom. The product
currently is being launched in 10 other European countries; however, the Company
does not currently anticipate that any of these markets, individually, will
provide sales volume equivalent to that generated in the United Kingdom. The
decline in animal health product revenues was due primarily to a general
continued weakening in the livestock markets and continuing concerns about
foot-and-mouth and mad cow diseases.
Worldwide consumer health care net revenue decreased 1% for 2001. Excluding
the negative impact of foreign exchange, worldwide consumer health care net
revenue was unchanged for
Wyeth and Subsidiaries 57
2001. U.S. consumer health care net revenue was unchanged for 2001 as a result
of higher sales of CHAP STICK, CALTRATE and ADVIL being offset by lower sales of
cough/cold/allergy products and FLEXAGEN.
International consumer health care net revenue decreased 3% for 2001 due
primarily to the divestiture of two international non-core products which
occurred early in 2001, as well as lower sales of cough/cold/allergy products.
These decreases were partially offset by higher sales of CENTRUM products,
CALTRATE and ADVIL.
2000 VS. 1999
Worldwide pharmaceutical net revenue increased 14% on an as-reported basis and
16% (primarily human pharmaceuticals) on a pro forma basis for 2000. Excluding
the negative impact of foreign exchange, pro forma worldwide pharmaceutical net
revenue increased 19% for 2000. Pro forma U.S. pharmaceutical net revenue
increased 22% for 2000 due primarily to higher sales of PREVNAR (introduced in
the 2000 first quarter), EFFEXOR XR (as a result of higher volume and market
share of new prescriptions, as well as expanded indications), PROTONIX
(introduced in the 2000 second quarter), PREMARIN products and animal health
products, and alliance revenue offset, in part, by lower sales of LODINE (due to
generic competition) and factor VIII.
Pro forma international pharmaceutical net revenue increased 7% for 2000 due
primarily to higher sales of MENINGITEC (introduced in the United Kingdom in the
1999 fourth quarter), EFFEXOR XR (as a result of higher volume and market share
of new prescriptions, as well as expanded indications) and REFACTO (introduced
in the 1999 second quarter).
Worldwide consumer health care net revenue increased 4% on an as-reported and
pro forma basis for 2000. Excluding the negative impact of foreign exchange,
worldwide consumer health care net revenue increased 6% for 2000. U.S. consumer
health care net revenue increased 5% for 2000 due primarily to higher sales of
CENTRUM products (including Centrum Performance, which was launched in the
United States in the 1999 fourth quarter), cough/cold/allergy products, CHAP
STICK and FLEXAGEN (introduced in the United States in the 2000 second quarter).
International consumer health care net revenue increased 2% for 2000 due
primarily to higher sales of CENTRUM products and CALTRATE offset, in part, by
lower sales of ANACIN.
The following table sets forth the percentage changes in 2001 as-reported and
2000 pro forma worldwide net revenue by operating segment and geographic area
compared with the prior year, including the effect volume, price and foreign
exchange had on these percentage changes:
[Enlarge/Download Table]
% Increase (Decrease) % Increase (Decrease)
Years Ended December 31, 2001 Years Ended December 31, 2000(1)(2)
---------------------------------------------- -------------------------------------------
Foreign Total Net Foreign Total Net
Volume Price Exchange Revenue Volume Price Exchange Revenue
---------------------------------------------------------------------------------------------------------------------------
PHARMACEUTICALS
United States 10% 5% -- 15% 15% 7% -- 22%
International 4% 1% (6)% (1)% 14% -- (7)% 7%
----------------------------------------------- -------------------------------------------
Total 8% 3% (2)% 9% 15% 4% (3)% 16%
=============================================== ===========================================
CONSUMER HEALTH CARE
United States (2)% 2% -- -- 4% 1% -- 5%
International (1)% 3% (5)% (3)% 4% 3% (5)% 2%
----------------------------------------------- -------------------------------------------
Total (2)% 2% (1)% (1)% 4% 2% (2)% 4%
=============================================== ===========================================
TOTAL
United States 8% 4% -- 12% 13% 5% -- 18%
International 4% 1% (6)% (1)% 12% 1% (7)% 6%
----------------------------------------------- -------------------------------------------
Total 6% 3% (2)% 7% 13% 3% (3)% 13%
=============================================== ===========================================
(1) Effective January 1, 2000, the financial results of certain subsidiaries
in Japan and India, which previously were included on an equity basis,
were consolidated in the results of the Company. Also effective January 1,
2000, the financial results of Immunex, which previously were consolidated
in the results of the Company, were deconsolidated and included on an
equity basis. Accordingly, alliance revenue was recorded in 2000 for
co-promotion agreements between the Company and Immunex. The 2000 pro
forma net revenue percentage changes reflect the respective consolidation
and deconsolidation of these subsidiaries and include alliance revenue
from Immunex, assuming all transactions occurred as of January 1, 1999.
Neither the consolidation nor the deconsolidation of these subsidiaries,
nor the inclusion of alliance revenue from Immunex, had any effect on
income from continuing operations in 2000.
(2) 2000 was restated to reflect the early adoption of new authoritative
accounting guidance as of January 1, 2001 reflecting certain rebates and
sales incentives (i.e., coupons and other rebate programs) as reductions
of revenues instead of selling and marketing expenses.
58 Wyeth and Subsidiaries
Operating Expenses
2001 VS. 2000
COST OF GOODS SOLD, as a percentage of Net revenue, decreased to 24.0% for 2001
compared with 24.7% for 2000. Excluding alliance revenue, cost of goods sold, as
a percentage of net sales, for 2001 was 24.5%, a 0.6% decrease from 25.1% in
2000. The margin improvement resulted from a favorable mix of higher margin
products in both the pharmaceuticals and consumer health care segments and lower
royalty expenses offset, in part, by increased costs associated with improving
the U.S. production supply chain processes.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES, as a percentage of Net revenue,
decreased to 36.7% for 2001 compared with 37.7% for 2000. The lower ratio of
selling, general and administrative expenses resulted from non-recurring launch
expenses, primarily media, related to pharmaceutical product launches in 2000,
and lower co-promotion expenses for ZIAC, due to reduced sales as a result of
generic competition. This ratio improvement was partially offset by an increase
in selling and marketing expenses in the Company's animal health division to
support the domestic launch of PROHEART 6, a new single dose, canine heartworm
preventative product.
RESEARCH AND DEVELOPMENT EXPENSES increased 11% for 2001 due primarily to
increased headcount and other research operating expenses, including higher
chemical and material costs, and ongoing clinical trials of pharmaceuticals in
several therapeutic categories. These increases were partially offset by lower
costs resulting from the timing of payments pursuant to certain pharmaceutical
collaborations and lower payments under licensing agreements. Pharmaceutical
research and development expenditures accounted for 96%, 96% and 95% of total
research and development expenditures in 2001, 2000 and 1999, respectively.
Pharmaceutical research and development expenses, as a percentage of worldwide
pharmaceutical net revenue, exclusive of infant nutritional sales and alliance
revenue, were 17%, 16% and 17% in 2001, 2000 and 1999, respectively.
2000 VS. 1999
COST OF GOODS SOLD, as a percentage of Net revenue, decreased to 24.7% for
2000 compared with 25.6% for 1999. Excluding alliance revenue,cost of goods
sold, as a percentage of net sales, for 2000 was 25.1%, a 0.5% decrease from
1999. A favorable mix of higher margin products in the pharmaceuticals segment
was offset, in part, by an increase in royalty expenses and costs associated
with improving the production and supply chain processes at certain
international sites.
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES, as a percentage of Net revenue,
increased to 37.7% for 2000 compared with 36.6% for 1999. Higher selling,
general and administrative expenses were due primarily to increased selling and
marketing expenses supporting higher field sales headcount and salaries,
promotional efforts for recent product launches and rapid growth products, and
direct-to-consumer programs. The increase in the ratio of these expenses, as a
percentage of Net revenue, was offset, in part, by deconsolidating Immunex in
2000 as these expenses carried a higher expense ratio and by consolidating Japan
and India in 2000 as their expense ratio was lower than the Company overall.
RESEARCH AND DEVELOPMENT EXPENSES increased 6% for 2000 due primarily to
certain advancements and ongoing clinical trials of pharmaceuticals in several
therapeutic categories, as well as additional payments for existing licensing
agreements offset, in part, by lower costs as a result of deconsolidating
Immunex in 2000.
Interest Expense and Other Income
2001 VS. 2000
INTEREST EXPENSE, NET increased substantially for 2001 due primarily to higher
weighted average debt outstanding, as compared with 2000. Weighted average debt
outstanding during 2001 and 2000 was $7,270.9 million and $3,853.0
million,respectively. The increase in interest expense was partially offset by
higher capitalized interest resulting from additional capital projects,
recognized during 2001, and lower interest rates on outstanding commercial
paper.
OTHER INCOME, NET increased 70% for 2001 due primarily to lower non-recurring
charges (as described below in the 2000 vs. 1999 Other income, net analysis),
higher gains on the sales of non-strategic assets and higher equity income.
2000 VS. 1999
INTEREST EXPENSE, NET decreased 73% for 2000 due primarily to an increase in
interest income as a result of higher cash and cash equivalents, as well as
lower debt resulting from the payoff of the $1,000.0 million of 7.70% notes on
February 15, 2000. In addition, on June 30, 2000, the Company used a portion of
the proceeds from the sale of the Cyanamid Agricultural Products business to pay
down a substantial portion of the outstanding commercial paper borrowings.
Weighted average debt outstanding during 2000 and 1999 was $3,853.0 million and
$4,889.0 million, respectively.
OTHER INCOME, NET decreased 37% for 2000 due primarily to non-recurring
charges(including: payments for access to various pharmaceutical collaborations,
costs associated with a consent decree entered into with the FDA in the 2000
third quarter (described below) and costs related to a product discontinuation)
and lower gains on the sales of non-strategic assets offset, in part, by an
insurance recovery of environmental costs, higher equity income and lower Year
2000 conversion costs. In conjunction with the consent decree identified above,
the Company recorded a pre-tax charge of $56.1 million which included payments
to the U.S. government and charges associated with actions required by the FDA
based on an inspection of the Marietta, Pennsylvania and Pearl River, New York
facilities. Pursuant to the consent decree, the Company will have a
comprehensive
Wyeth and Subsidiaries 59
inspection performed by expert consultants to determine compliance with current
Good Manufacturing Practices.
2001, 2000 and 1999 Unusual Transactions
During the 2001 third quarter, the Company recorded a charge of $950.0 million
($615.0 million after-tax or $0.46 per share-diluted) relating to the litigation
brought against the Company regarding the use of the diet drugs Redux or
Pondimin. An initial litigation charge of $4,750.0 million ($3,287.5 million
after-tax or $2.51 per share-diluted) was recorded in the 1999 third quarter
followed by an additional litigation charge of $7,500.0 million ($5,375.0
million after-tax or $4.11 per share-diluted) recorded in the 2000 fourth
quarter. The combination of these three charges represents the estimated total
amount required to resolve all diet drug litigation, including all anticipated
funding requirements for the nationwide, class action settlement and costs to
resolve the claims of any members of the settlement class who in the future may
exercise an intermediate or back-end opt out right. Additionally, these charges
will cover any remaining administrative and legal expenses and costs associated
with the resolution of the claims of the initial opt outs and primary pulmonary
hypertension claimants (see Note 12 to the Consolidated Financial Statements and
the "Liquidity, Financial Condition and Capital Resources" section herein for
further discussion relating to the Company's additional financing requirements
for the future settlement payments).
During the 2000 first quarter, the Company and Warner-Lambert Company
terminated their merger agreement. The Company recorded income of $1,709.4
million ($1,111.1 million after-tax or $0.85 per share-diluted) in income from
continuing operations resulting from the receipt of a $1,800.0 million
termination fee provided for under the merger agreement offset, in part, by
certain related expenses (see Note 3 to the Consolidated Financial Statements).
In November 2000, the Company and Immunex completed a public equity offering
allowing the Company to sell 60.5 million shares of Immunex common stock.
Proceeds to the Company were $2,404.9 million, resulting in a gain on the sale
of $2,061.2 million ($1,414.9 million after-tax or $1.08 per share-diluted). The
Company used the net proceeds from the sale of its Immunex common stock to
reduce outstanding commercial paper and for other general corporate purposes
(see Note 2 to the Consolidated Financial Statements).
In November 2000, in accordance with an FDA request, the Company immediately
ceased global production and shipments of any products containing PPA and
voluntarily withdrew any such products from customer warehouses and retail store
shelves. As a result, the Company recorded a special charge of $80.0 million
($52.0 million after-tax or $0.04 per share-diluted) to provide primarily for
product returns and the write-off of inventory (see Note 3 to the Consolidated
Financial Statements).
During the 2000 fourth quarter, the Company recorded a special charge of
$267.0 million ($173.0 million after-tax or $0.13 per share-diluted) related to
the discontinuation of certain products. The special charge provided for fixed
asset impairments, inventory write-offs, severance obligations, idle plant costs
and contract termination costs (see Note 3 to the Consolidated Financial
Statements).
At December 31, 2000, the Company performed goodwill and other intangible
reviews and noted that projected profitability and future cash flows associated
with generic pharmaceuticals and the SOLGAR consumer health care product line
would not be sufficient to recover the remaining goodwill related to these
product lines. As a result, the Company recorded a charge of $401.0 million
($341.0 million after-tax or $0.26 per share-diluted) to write down the carrying
value of goodwill related to these product lines, to fair value, representing
discounted future cash flows (see Note 3 to the Consolidated Financial
Statements).
During the 1999 second quarter, the Company recorded a special charge
aggregating $82.0 million ($53.0 million after-tax or $0.04 per share-diluted)
for estimated costs associated with the suspension of shipments and the
voluntary market withdrawal of ROTASHIELD, the Company's rotavirus vaccine (see
Note 3 to the Consolidated Financial Statements).
60 Wyeth and Subsidiaries
Income (Loss) from Continuing Operations before Taxes
The following table sets forth worldwide income (loss) from continuing
operations before taxes by operating segment together with the percentage
changes from the comparable periods in the prior year on an as-reported basis:
[Enlarge/Download Table]
2001 VS. 2000 2000 vs. 1999
(Dollar amounts in millions) YEARS ENDED DECEMBER 31, ------------- -------------
INCOME (LOSS) FROM CONTINUING --------------------------------------------- % Increase % Increase
OPERATIONS BEFORE TAXES(1) 2001 2000 1999 (Decrease) (Decrease)
---------------------------------------------------------------------------------------------------------------------
Operating Segment:
Pharmaceuticals $ 3,503.5 $ 2,919.5 $ 2,538.6 20% 15%
Consumer Health Care 592.1 626.6 594.6 (6)% 5%
--------------------------------------------------------------------------------
4,095.6 3,546.1 3,133.2 15% 13%
Corporate(2) (1,226.9) (4,647.1) (5,040.5) (74)% (8)%
--------------------------------------------------------------------------------
Total(3) $ 2,868.7 $(1,101.0) $(1,907.3) -- (42)%
================================================================================
(1) Income (loss) from continuing operations before taxes included goodwill
amortization for 2001, 2000 and 1999 as follows: Pharmaceuticals--$136.8,
$147.8 and $154.3 and Consumer Health Care--$23.7, $31.8 and $32.7,
respectively.
(2) 2001, 2000 and 1999 Corporate included litigation charges of $950.0,
$7,500.0 and $4,750.0, respectively, relating to the litigation brought
against the Company regarding the use of the diet drugs REDUX or PONDIMIN.
The charges provide for all anticipated payments in connection with the
nationwide, class action settlement, anticipated costs to resolve the
claims of any members of the settlement class who in the future may
exercise an intermediate or back-end opt out right, costs to resolve the
claims of PPH claimants and initial opt out claimants, and administrative
and litigation expenses, net of insurance.
2000 Corporate also included:
- Income of $1,709.4 resulting from the receipt of a $1,800.0
termination fee provided for under the merger agreement with
Warner-Lambert Company offset, in part, by certain related
expenses.
- Income of $2,061.2 related to the Company selling a portion of
its investment in Immunex common stock in a public equity
offering with Immunex.
- Goodwill impairment of $401.0 related to the goodwill
associated with generic pharmaceuticals and the SOLGAR
consumer health care product line.
- A special charge of $80.0 related to the voluntary ceasing of
production and subsequent market withdrawal of products
containing PPA.
- A special charge of $267.0 related to costs associated with
certain product discontinuations.
1999 Corporate also included a special charge of $82.0 related to the
suspension of shipments and the voluntary market withdrawal of ROTASHIELD,
the Company's rotavirus vaccine.
Excluding the 2001, 2000 and 1999 litigation charges, 2000 termination
fee, 2000 gain on the sale of Immunex common stock, 2000 goodwill
impairment, and 2000 and 1999 special charges, Corporate expenses, net
increased 63% for 2001 and decreased 19% for 2000.
(3) Excluding the 2001, 2000 and 1999 litigation charges, 2000 termination
fee, 2000 gain on the sale of Immunex common stock, 2000 goodwill
impairment, and 2000 and 1999 special charges, total income from
continuing operations before taxes increased 13% for 2001 and 15% for
2000.
The following explanations of changes in income (loss) from continuing
operations before taxes, by operating segment, for 2001 compared with 2000, and
2000 compared with 1999, exclude items listed in footnote (2) to the table
above:
PHARMACEUTICALS
Worldwide pharmaceutical income from continuing operations before taxes
increased 20% (22% for human pharmaceuticals) for 2001 due primarily to higher
U.S. net revenue (favorable product mix) and other income, net (primarily lower
non- recurring charges and higher gains on asset sales) offset, in part, by
higher selling, general and administrative expenses and research and development
expenses. Higher selling, general and administrative expenses were due primarily
to increased promotional expenses to support existing product lines and sales
force expansion offset, in part, by a decrease in marketing expenses related to
product launches that occurred in 2000.
Worldwide pharmaceutical income from continuing operations before taxes
increased 15% (11% for human pharmaceuticals) for 2000 due primarily to higher
worldwide net revenue (including alliance revenue) offset, in part, by higher
selling, general and administrative expenses, research and development expenses,
and other expenses (primarily non-recurring charges). Higher selling, general
and administrative expenses were due primarily to increased media and
promotional expenses to support product launches and existing product lines
through increased headcount.
CONSUMER HEALTH CARE
Worldwide consumer health care income from continuing operations before taxes
decreased 6% for 2001 due primarily to lower worldwide sales and lower other
income, net (primarily lower gains on sales of non-strategic assets). Worldwide
consumer health care income from continuing operations before taxes increased 5%
for 2000 due primarily to higher worldwide sales.
CORPORATE
Corporate expenses, net increased 63% for 2001 due primarily to higher
interest expense, net and lower other income related to
Wyeth and Subsidiaries 61
an insurance recovery of environmental costs recorded in 2000 offset, in part,
by lower general and administrative expenses.
Corporate expenses, net decreased 19% for 2000 due primarily to lower
interest expense, net and current year insurance recoveries related to
environmental costs offset, in part, by lower gains on sales of non-strategic
assets, higher general and administrative expenses, and costs related to a
product discontinuation.
Effective Tax Rate
The effective tax rate for 2001 was 24.1% compared with 25.5% for 2000 and 27.1%
for 1999. The downward trend in the effective tax rates was due primarily to an
increased benefit from manufacturing in lower taxed jurisdictions and higher
research credits.
Income (Loss) and Diluted Earnings (Loss) per Share from Continuing Operations
Income and diluted earnings per share from continuing operations in 2001 were
$2,285.3 million and $1.72, respectively, compared with a loss and diluted loss
per share from continuing operations of $901.0 million and $0.69 in 2000,
respectively. Loss and diluted loss per share from continuing operations in 1999
were $1,207.2 million and $0.92, respectively. The income (loss) from continuing
operations for 2001, 2000 and 1999 included the following unusual items:
[Enlarge/Download Table]
Diluted Earnings (Loss) Per
Income (Loss) Share From Continuing
From Continuing Operations Operations
(In millions, except per share amounts) -------------------------------------- --------------------------------------
YEARS ENDED DECEMBER 31, 2001 2000 1999 2001 2000 1999
---------------------------------------------------------------------------------------------------------------------------
Income from continuing operations
before unusual items and including
the dilutive effect of common
stock equivalents (CSE) $ 2,900.3 $ 2,514.0 $ 2,133.3 $ 2.18 $ 1.90 $ 1.61
Dilutive effect of CSE* -- -- -- -- 0.02 0.02
-------------------------------------- --------------------------------------
$ 2,900.3 $ 2,514.0 $ 2,133.3 $ 2.18 $ 1.92 $ 1.63
Warner-Lambert Company
termination fee -- 1,111.1 -- -- 0.85 --
Gain on sale of Immunex
common stock -- 1,414.9 -- -- 1.08 --
Redux and Pondimin diet drug
litigation charges (615.0) (5,375.0) (3,287.5) (0.46) (4.11) (2.51)
Goodwill impairment -- (341.0) -- -- (0.26) --
Special charges:
Voluntary market withdrawals -- (52.0) (53.0) -- (0.04) (0.04)
Product discontinuations -- (173.0) -- -- (0.13) --
-------------------------------------- --------------------------------------
Income (loss) from continuing
operations $ 2,285.3 $ (901.0) $(1,207.2) $ 1.72 $ (0.69) $ (0.92)
====================================== ======================================
* The $0.02 per share benefit represents the impact on income from
continuing operations of excluding the dilutive effect of CSE. 2001
diluted earnings per share from continuing operations of $2.18 includes
the dilutive impact of CSE.
For further details related to the items listed in the table above, refer to
the discussion of "2001, 2000 and 1999 Unusual Transactions" herein.
Excluding all unusual items from the 2001 and 2000 results listed in the
table above and including the $0.02 per share dilutive effect of common stock
equivalents in the 2000 results, both income and diluted earnings per share from
continuing operations in 2001 increased 15% compared with 2000. The increases
were due primarily to higher U.S. pharmaceutical net revenue and higher other
income, net offset, in part, by higher selling, general and administrative
expenses, research and development expenses, and interest expense, net.
Excluding all unusual items from the 2000 and 1999 results listed in the
table above and including the $0.02 per share dilutive effect of common stock
equivalents in 2000 and 1999 results, both income and diluted earnings per share
from continuing operations in 2000 increased 18% compared with 1999. The
increases were due primarily to higher worldwide sales of pharmaceuticals and
lower interest expense, net offset, in part, by higher selling, general and
administrative expenses and research and development expenses.
Discontinued Operations
On June 30, 2000, the Company announced that it had completed the sale of the
Cyanamid Agricultural Products business to BASF. Under the terms of the
definitive agreement, BASF paid the Company $3,800.0 million in cash and assumed
certain debt. As a result, the Company recorded an after-tax loss on the sale
62 Wyeth and Subsidiaries
of this business of $1,573.0 million or $1.20 per share-diluted and reflected
this business as a discontinued operation beginning in the 2000 first quarter
and restated all prior periods presented (see Note 2 to the Consolidated
Financial Statements).
LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES
CASH AND CASH EQUIVALENTS decreased $899.6 million, while total debt increased
by $7,001.1 million in 2001. The activity of these cash flows during 2001
related primarily to the following items:
- Payments of $7,257.9 million related to the REDUX and PONDIMIN
litigation. These payments were financed primarily from borrowing
activities. As discussed in Note 12 to the Consolidated Financial
Statements, during 1999, the Company announced a nationwide, class
action settlement to resolve litigation brought against the Company
regarding the use of the diet drugs REDUX or PONDIMIN. Payments to
provide settlement benefits, if needed, may continue for approximately
16 years after final judicial approval. Payments made to date and
future payments related to the diet drug litigation are anticipated to
be financed through existing cash resources, cash flows from operating
activities, additional commercial paper borrowings, as well as term
debt financings and international earnings remitted back to the United
States, if necessary.
- Capital expenditures of $1,924.3 million due primarily to new
production capacity expansion worldwide, including biotechnology
facilities, research and development facilities, and to improve
compliance of U.S. supply chain processes. A similar level of capital
expenditures is expected to continue in 2002.
- Dividends totaling $1,211.1 million consisting primarily of the
Company's annual common stock dividend of $0.92 per share that provided
the Company's stockholders with an approximate yield of 1.5%.
- Net marketable security purchases, throughout 2001, of $941.0 million
to support an effective cash management strategy.
- Contributions to fund the Company's defined benefit pension plans
totaling $429.7 million.
- An increase in other current assets, excluding deferred taxes, of
$395.8 million primarily for anticipated tax refunds.
- An increase in inventories of $273.1 million primarily related to
planning for expected product demand.
These cash uses were partially offset by other net cash generated by
operations of $3,909.6 million, proceeds from sales of assets of $408.2 million,
proceeds from the exercise of stock options of $224.6 million and the proceeds
from borrowing activities identified above.
ADDITIONAL LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCE INFORMATION
At December 31, 2001, the carrying value of cash equivalents approximated fair
value due to the short-term, highly liquid nature of cash equivalents, which
have original maturities of three months or less. Interest rate fluctuations
would not have a significant effect on the fair value of cash equivalents held
by the Company.
The Company maintains a $2,000.0 million credit facility, which supports
borrowings under the commercial paper program and terminates on July 31, 2002.
Since the $2,000.0 million credit facility terminates in less than one year,
commercial paper outstanding of $1,817.2 million, supported by this facility,
was classified as current debt in Loans payable as of December 31, 2001. In
March 2001, the Company obtained an additional revolving credit facility of
$3,000.0 million to support its commercial paper program. The Company offers its
commercial paper in a very liquid market commensurate with its short-term credit
ratings from Moody's (P2), S&P (A1) and Fitch (A1). In March 2002, subsequent to
the date of the "Report of Independent Public Accountants," the Company renewed
the $3,000.0 million credit facility for an additional 364-day term, and reduced
the $2,000.0 million credit facility to $1,000.0 million until it matures on
July 31, 2002.
In March 2001, the Company issued three tranches of Notes in a transaction
exempt from registration under the Securities Act, pursuant to Rule 144A, as
follows:
- $500.0 million 5.875% Notes due March 15, 2004
- $1,000.0 million 6.25% Notes due March 15, 2006
- $1,500.0 million 6.70% Notes due March 15, 2011
The interest rate payable on each series of Notes is subject to an increase
of 0.25 percentage points per level of downgrade in the Company's credit rating
by Moody's or S&P. However, the total adjustment to the interest rate for the
series of Notes cannot exceed two percentage points. There is no adjustment to
the interest rate payable on each series of Notes for the first single level
downgrade in the Company's credit rating by S&P. In the case of the $1,500.0
million 6.70% Notes, the interest rate in effect on March 15, 2006 for such
Notes will, thereafter, become the effective interest rate until maturity on
March 15, 2011. The Company would incur a total of approximately $7.5 million of
additional annual interest expense for every 0.25 percentage point increase in
the interest rate. If Moody's or S&P subsequently were to increase the Company's
credit rating, the interest rate payable on each series of Notes would be
subject to a decrease of 0.25 percentage points for each level of credit rating
increase. The interest rate payable for the series of Notes cannot be reduced
below the original coupon rate of each series of Notes.
In addition to the Notes issued in March 2001, the Company has outstanding:
$250.0 million 6.50% Notes due October
Wyeth and Subsidiaries 63
2002, $1,000.0 million 7.90% Notes due February 2005 and $250.0 million 7.25%
debentures due March 2023.
The Company has a common stock repurchase program under which the Company
is authorized, at December 31, 2001, to repurchase 6,492,460 additional shares
in the future. Depending upon market conditions, among other things, the Company
may make limited repurchases of its common stock to offset stock issuances in
connection with exercises of stock options during 2002.
Management remains confident that cash flows from operating activities and
available financing resources will be adequate to fund the Company's operations,
pay all amounts related to the REDUX and PONDIMIN diet drug litigation, pay
dividends, maintain the ongoing programs of capital expenditures, including the
amount already committed at December 31, 2001 of $851.6 million, and repay both
the principal and interest on its outstanding obligations, without requiring the
disposition of any significant strategic core assets or businesses.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The Company is exposed to market risk from changes in foreign currency exchange
rates and interest rates that could impact its financial position, results of
operations and cash flows. The Company manages its exposure to these market
risks through its regular operating and financing activities and, when deemed
appropriate, through the use of derivative financial instruments. The Company
uses derivative financial instruments as risk management tools and not for
trading purposes. In addition, derivative financial instruments are entered into
with a diversified group of major financial institutions in order to manage the
Company's exposure to non-performance on such instruments.
FOREIGN CURRENCY RISK MANAGEMENT: The Company generates a portion of Net
revenue from sales to customers located outside the United States, principally
in Europe. International sales are generated mostly from international
subsidiaries in the local countries with the sales typically denominated in the
local currency of the respective country. These subsidiaries also incur most of
their expenses in the local currency. Accordingly, most international
subsidiaries use the local currency as their functional currency. International
business, by its nature, is subject to risks including, but not limited to:
differing economic conditions, changes in political climate, differing tax
structures, other regulations and restrictions, and foreign exchange rate
volatility. Accordingly, future results could be adversely impacted by changes
in these or other factors.
The Company has established programs to protect against adverse changes in
exchange rates due to foreign currency volatility. The Company believes that the
foreign currency risks to which it is exposed are not reasonably likely to have
a material adverse effect on the Company's financial position, results of
operations or cash flows due to the high concentration of sales in the United
States. No single foreign currency accounted for 5% or more of 2001 or 2000
worldwide net revenue, except for the British pound sterling, which accounted
for 5% and 7% of 2001 and 2000 worldwide net revenue, respectively. On January
1, 2002, 12 member countries of the European Union adopted the Euro as a new
common legal currency. Collectively, these countries accounted for 11% of both
2001 and 2000 worldwide Net revenue.
INTEREST RATE RISK MANAGEMENT: The fair value of the Company's fixed-rate
long-term debt is sensitive to changes in interest rates. Interest rate changes
result in gains/losses in the market value of this debt due to differences
between the market interest rates and rates at the inception of the debt
obligation. The Company manages this exposure to interest rate changes primarily
through the use of interest rate swaps. The Company has swapped an appropriate
amount of its fixed rate debt into variable rate debt to maintain a
fixed-to-variable ratio of approximately 1 to 1 on its total debt position,
consistent with the Company's debt management philosophy.
At December 31, 2001, the notional/contract amounts, carrying values and
fair values of the Company's financial instruments were as follows:
[Download Table]
(Dollar amounts in millions) Notional/
DESCRIPTION Contract Amount Carrying Value Fair Value
--------------------------------------------------------------------------------
Forward contracts(1) $ 438.8 $ 17.9 $ 17.9
Option contracts(1) 796.4 12.9 12.9
Interest rate swaps 1,500.0 12.8 12.8
Outstanding debt(2) 9,445.5 9,454.6 9,607.7
(1) If the value of the U.S. dollar were to increase or decrease by 10%, in
relation to all hedged foreign currencies, the net receivable on the
forward and option contracts would decrease or increase by approximately
$68.6.
(2) If the interest rates were to increase or decrease by one percentage
point, the fair value of the outstanding debt would increase or decrease
by approximately $215.1.
The estimated fair values approximate amounts at which these financial
instruments could be exchanged in a current transaction between willing parties.
Therefore, fair values are based on estimates using present value and other
valuation techniques that are significantly affected by the assumptions used
concerning the amount and timing of estimated future cash flows and discount
rates that reflect varying degrees of risk. Specifically, the fair value of
forward contracts and interest rate swaps reflects the
64 Wyeth and Subsidiaries
present value of the future potential gain if settlement were to take place on
December 31, 2001; the fair value of option contracts reflects the present value
of future cash flows if the contracts were settled on December 31, 2001; and the
fair value of outstanding debt instruments reflects a current yield valuation
based on observed market prices as of December 31, 2001.
FORWARD-LOOKING INFORMATION AND FACTORS THAT MAY AFFECT FUTURE RESULTS
This Annual Report, including management's discussion and analysis set forth
herein, contains certain forward-looking statements, including, among other
things, statements regarding the Company's results of operations, future impact
of presently known trends, Euro currency, competition, liquidity, financial
condition and capital resources, PREMARIN, ENBREL supply, MENINGITEC sales,
foreign currency and interest rate risk, the nationwide, class action settlement
relating to REDUX and PONDIMIN, and additional litigation charges related to
REDUX and PONDIMIN including those for opt outs. These forward-looking
statements are based on current expectations of future events that involve risks
and uncertainties, including, without limitation, risks associated with the
inherent uncertainty of pharmaceutical research, product development,
manufacturing and commercialization, and economic conditions, including interest
and currency exchange rate fluctuations, the impact of competitive or generic
products, product liability and other types of lawsuits, the impact of
legislative and regulatory compliance and product approval obtainment, and
patents. From time to time, we also may provide oral or written forward-looking
statements in other materials we release to the public. However, the Company
assumes no obligation to publicly update any forward-looking statements, whether
as a result of new information, future events or otherwise. Certain additional
factors which could cause the Company's actual results to differ materially from
expected and historical results have been identified by the Company in Exhibit
99 to the Company's 2000 Annual Report on Form 10-K, and the Company's 2001
Annual Report on Form 10-K, which will be filed by April 1, 2002, as well as the
sections identified below.
FUTURE IMPACT OF PRESENTLY KNOWN TRENDS
PENSION ASSETS AND OTHER POSTRETIREMENT PLAN ASSUMPTIONS
As a result of the recent retraction in the global equity markets, the Company
has experienced a significant reduction in the market value of assets held by
the Company's pension plan. The Company's pension plan assets also were
decreased by the normal annual benefit payments, which historically have been
offset by the positive actual return on plan assets. In order to mitigate the
decline, the Company made a $400.0 million funding contribution to the U.S.
Non-bargaining pension plan in December 2001. Despite the contribution, the
market value decline is expected to negatively impact pension expense in 2002.
In addition, based on an annual internal study of actuarial assumptions, the
expected long-term rate of return on plan assets and discount rate both have
been decreased by 25 basis points to 9.25% and 7.25%, respectively. As a result
of these developments, the 2002 net periodic benefit cost for pensions is
anticipated to be approximately $40.0 million to $50.0 million higher than in
2001.
The Company also has reviewed the principal actuarial assumptions relating
to its other postretirement plan. In response to the recent increase in health
care costs in the United States, the Company has increased the health care cost
trend rate to 9.5% for 2001, decreasing to 5.0% by 2005. In reviewing
postretirement claims data and other related assumptions, the Company believes
that this trend rate increase appropriately reflects the trend aspects of the
Company's postretirement plan as of December 31, 2001. As a result of the
increase in the health care cost trend rate, the 2002 net periodic benefit cost
for other postretirement benefits is anticipated to be approximately $10.0
million to $20.0 million higher than in 2001.
PROPOSED ACQUISITION OF IMMUNEX BY AMGEN
In December 2001, Amgen Inc. and Immunex signed a definitive agreement providing
for Amgen to acquire Immunex in a merger transaction. The terms of the agreement
require that each share of Immunex common stock be exchanged for 0.44 shares of
Amgen common stock and $4.50 in cash. Upon completion of the merger transaction,
the Company would receive over $1,000.0 million in cash proceeds, based upon the
number of shares the Company owned of Immunex as of December 31, 2001. The
Company may use these cash proceeds to repay outstanding debt obligations, fund
ongoing programs of capital expenditures or fund other working capital
requirements.
POTENTIAL TAX REFUND
On October 5, 2001, the U.S. District Court for the District of Columbia entered
judgment in favor of the Company in Boca Investerings Partnership v. U.S., in
which the Company challenged the disallowance by the Internal Revenue Service
(IRS) of a capital loss deduction in 1990 related to a partnership investment.
The Court ordered the IRS to refund the tax paid, approximately $226.0 million,
together with interest. The IRS has appealed the decision and, as a result, the
Company has not recognized this anticipated refund in its 2001 Consolidated
Financial Statements.
IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS
As of January 1, 2002, the Company adopted SFAS No. 142, Goodwill and Other
Intangible Assets, which requires, among other things, the ceasing of
amortization of goodwill and certain indefinite lived intangibles. In accordance
with the adoption of SFAS No. 142, the Company will cease amortizing goodwill.
Included in Selling, general and administrative expenses for 2001
Wyeth and Subsidiaries 65
was approximately $160.5 million ($153.9 million after-tax or $0.12 per
share-diluted) of goodwill amortization. The Company currently is assessing the
impact the new impairment testing requirements may have on its financial
position, results of operations and cash flows.
In April 2001, the EITF reached a consensus on Issue No. 00-25, Vendor
Income Statement Characterization of Consideration Paid to a Reseller of the
Vendor's Products. EITF No. 00-25 requires the cost of certain vendor
considerations be classified as a reduction of revenue rather than a marketing
expense. The Company will adopt the provisions of EITF No. 00-25 effective
January 1, 2002. The adoption of EITF No. 00-25 will result in reclassifications
of certain marketing expenses to revenues and will have no effect on income from
continuing operations. The Company does not anticipate the adoption of this
consensus to significantly affect the growth rate of net revenues.
CRITICAL ACCOUNTING POLICIES
The Company does not consider any specific accounting policies to be critical to
the economic success of the entity. The Company does not participate in, nor has
created, any off-balance sheet financing or other off-balance sheet special
purpose entities, other than operating leases. In addition, the Company does not
enter into any derivative financial instruments for trading purposes and uses
derivative financial instruments solely for managing its exposure to certain
market risks from changes in foreign currency exchange rates and interest rates.
Euro Currency
On January 1, 2002, Euro banknotes and coins were introduced in 12 of the 15
member states of the European Union. The new common legal currency replaces the
individual national currencies that currently are being withdrawn. The Company
has effectively converted to the new single currency by identifying critical
areas affected by the change and by successfully implementing programs to
facilitate transition. The costs related to the Euro conversion and transition
period did not have a material adverse effect on the Company's financial
position, results of operations or cash flows.
Competition
The Company operates in the highly competitive pharmaceutical and consumer
health care industries. The Company is not dependent on any one patent-protected
product or line of products for a substantial portion of its net revenues or
results of operations. PREMARIN, the Company's principal conjugated estrogens
product manufactured from pregnant mare's urine, and related products PREMPRO
and PREMPHASE (which are single tablet combinations of the conjugated estrogens
in PREMARIN and the progestin medroxyprogesterone acetate), are the leaders in
their categories and contribute significantly to net revenue and results of
operations. PREMARIN's natural composition is not subject to patent protection
(although PREMPRO has patent protection). The principal uses of PREMARIN,
PREMPRO and PREMPHASE are to manage the symptoms of menopause and to prevent
osteoporosis, a condition involving a loss of bone mass in postmenopausal women.
Estrogen-containing products manufactured by other companies have been marketed
for many years for the treatment of menopausal symptoms, and several of these
products also have an approved indication for the prevention of osteoporosis.
During the past several years, other manufacturers have introduced products for
the treatment and/or prevention of osteoporosis. New products containing
different estrogens than those found in PREMPRO and PREMPHASE and having many
forms of the same indications also have been introduced. Some companies have
attempted to obtain approval for generic versions of PREMARIN. These products,
if approved, would be routinely substitutable for PREMARIN and related products
under many state laws and third-party insurance payer plans. In May 1997, the
FDA announced that it would not approve certain synthetic estrogen products as
generic equivalents of PREMARIN given known compositional differences between
the active ingredient of these products and PREMARIN. Although the FDA has not
approved any generic equivalent to PREMARIN to date, PREMARIN will continue to
be subject to competition from existing and new competing estrogen and other
products for its approved indications and may be subject to generic competition
from either synthetic or natural conjugated estrogens products in the future. At
least one other company has announced that it is in the process of developing a
generic version of PREMARIN from the same natural source, and the Company
currently cannot predict the timing or outcome of these or any other efforts.
The Company has been experiencing inconsistent results on dissolution testing
of certain dosage strengths of PREMARIN and is working with the FDA to resolve
this issue. Until this issue is resolved, supply shortages of one or more dosage
strengths may occur. Although these shortages may adversely affect PREMARIN
sales in one or more accounting periods, the Company believes that, as a result
of current adequate inventory levels and the Company's enhanced process
controls, testing protocols and an ongoing formulation improvement project,
overall PREMARIN family sales will not be significantly impacted.
ENBREL Supply
Although the market demand for ENBREL is increasing, the sales growth currently
is constrained by limits on the existing source of supply. This is expected to
continue until the retrofitting of a Rhode Island facility is completed and
approved, which is expected to occur in 2002. If the market demand continues to
grow, there may be further supply constraints even after the Rhode Island
facility begins producing ENBREL. The current plan for the longer term includes
a new manufacturing facility, which is being constructed in Ireland.
66 Wyeth and Subsidiaries
DIRECTORS AND OFFICERS
BOARD OF DIRECTORS
John R. Stafford (1)
Chairman of the Board
Clifford L. Alexander, Jr. (2,4)
President, Alexander & Associates, Inc.
Frank A. Bennack, Jr. (1,3,5)
President and Chief Executive Officer, The Hearst Corporation
Richard L. Carrion (3,5)
Chairman, President and Chief Executive Officer, Popular, Inc.
and Banco Popular de Puerto Rico
Robert Essner (1)
President and Chief Executive Officer
John D. Feerick (2,3)
Dean, Fordham University School of Law
John P. Mascotte (2,3,5)
Retired President and Chief Executive Officer, Blue Cross
and Blue Shield of Kansas City, Inc.
Mary Lake Polan, M.D., Ph.D., M.P.H. (2,4)
Chairman and Professor, Department of Gynecology and Obstetrics,
Stanford University School of Medicine
Ivan G. Seidenberg (1,4,5)
President and Co-Chief Executive Officer, Verizon Communications, Inc.
Walter V. Shipley (3,5)
Retired Chairman of the Board, The Chase Manhattan Corporation
John R. Torell III (2,4)
Partner
Core Capital Group
DIRECTOR EMERITUS
John W. Culligan
Retired -- Former Chairman of the Board
PRINCIPAL CORPORATE
OFFICERS
John R. Stafford (6,7,8,9,10)
Chairman of the Board
Robert Essner (6,7,8,9,10)
President and Chief Executive Officer
Louis L. Hoynes, Jr. (6,7,8,9,10)
Executive Vice President and General Counsel
L. Patrick Gage, Ph.D. (6,7,8,9)
Senior Vice President -- Science and Technology
Kenneth J. Martin (6,7,8,9,10)
Senior Vice President and Chief Financial Officer
Bernard J. Poussot (6,7,8,9)
Senior Vice President
Lawrence V. Stein (7,8)
Senior Vice President and Deputy General Counsel
John B. Adams
Vice President -- Corporate Development
Egon E. Berg
Vice President and Associate General Counsel
Bruce Fadem
Vice President -- Corporate Information Services and Chief Information Officer
Leo C. Jardot
Vice President -- Government Relations
Paul J. Jones (7,8)
Vice President and Comptroller
Rene R. Lewin (6,7,8,9,10)
Vice President -- Human Resources
Jack M. O'Connor (9)
Vice President and Treasurer
Marily H. Rhudy (6,8)
Vice President -- Public Affairs
Jeffrey S. Sherman
Vice President and Associate General Counsel
Steven A. Tasher (7)
Vice President -- Environmental Affairs and Facilities Operations,
and Associate General Counsel
Justin R. Victoria
Vice President -- Investor Relations
Mary Katherine Wold (9)
Vice President -- Taxes
Eileen M. Lach
Secretary and Associate
General Counsel -- International
PRINCIPAL DIVISION AND SUBSIDIARY OFFICERS
Fort Dodge Animal Health Division
E. Thomas Corcoran (6,8)
President
Specialty Pharmaceuticals Division
David G. Strunce
President
Wyeth Consumer Healthcare
Ulf Wiinberg (6,7,8,9)
President
Wyeth Consumer Healthcare International
Bruce I. Macphail (8)
President
Wyeth Consumer Healthcare U.S.
Douglas A. Rogers (8)
President
Wyeth Pharmaceuticals
Bernard J. Poussot (6,7,8,9)
President
Wyeth Pharmaceuticals -- Europe, Middle East and Africa
Robert N. Power (8)
President
Wyeth Pharmaceuticals -- Intercontinental Region
Mark M. Larsen (8)
President
Wyeth Pharmaceuticals -- North America
Joseph M. Mahady (6,8)
President
Wyeth Research
L. Patrick Gage, Ph.D. (6,7,8,9)
President
Wyeth Vaccines and Nutrition
Kevin L. Reilly
President
(1) Executive Committee
(2) Audit Committee
(3) Compensation and Benefits Committee
(4) Corporate Issues Committee
(5) Nominating and Governance Committee
(6) Management Committee
(7) Law/Regulatory Review Committee
(8) Operations Committee
(9) Human Resources and Benefits Committee
(10) Retirement Committee
Wyeth and Subsidiaries 67
CORPORATE DATA
EXECUTIVE OFFICES
Wyeth
Five Giralda Farms
Madison, NJ 07940
(973) 660-5000
STOCK TRADING INFORMATION
Wyeth stock is listed on the New York Stock Exchange (ticker symbol: WYE).
INDEPENDENT PUBLIC ACCOUNTANTS
Arthur Andersen LLP
1345 Avenue of the Americas
New York, NY 10105
ANNUAL MEETING
The Annual Meeting of Stockholders will be held on Thursday, April 25, 2002 at
the Headquarters Plaza Hotel in Morristown, New Jersey.
STOCKHOLDER ACCOUNT INFORMATION
The Bank of New York is the transfer agent, registrar, dividend disbursing agent
and dividend reinvestment agent for the Company. Stockholders of record with
questions about lost certificates, lost or missing dividend checks, or
notification of change of address should contact:
The Bank of New York
P.O. Box 11002
Church Street Station
New York, NY 10286
(800) 565-2067 (Inside the United States and Canada)
(610) 312-5303 (Outside the United States and Canada)
For the hearing impaired: (888) 269-5221 (TDD)
Via e-mail: shareowner-svcs@bankofny.com
Internet address: www.stockbny.com
BUYDIRECT STOCK PURCHASE AND SALE PLAN
The BuyDIRECT plan provides stockholders of record and new investors with a
convenient way to make cash purchases of the Company's common stock and to
automatically reinvest dividends. Inquiries should be directed to The Bank of
New York.
FORM 10-K
A copy of the Company's Annual Report on Form 10-K may be obtained by any
stockholder without charge through The Bank of New York.
EQUAL EMPLOYMENT OPPORTUNITY
Our established affirmative action and equal employment programs demonstrate our
long-standing commitment to provide job and promotional opportunities for all
qualified persons regardless of age, color, disability, national origin, race,
religion, sex, sexual orientation, status as a Vietnam-era veteran or a special
disabled veteran, or any military uniformed services obligation.
POLICY ON HEALTH, SAFETY AND ENVIRONMENTAL PROTECTION
Copies of the Company's "Policy on Health, Safety and Environmental Protection"
and "2000 Environmental and Safety Report" may be obtained upon
written request to:
Wyeth
Department of Environment and Safety
Five Giralda Farms
Madison, NJ 07940
WYETH ON THE INTERNET
Wyeth's Internet address is:
www.wyeth.com
TRADEMARKS
Product designations appearing in differentiated type are trademarks.
Design: Arnold Saks Associates
Major Photography: Mark Tuschman
68 Wyeth and Subsidiaries Text: Fulton Communications
Dates Referenced Herein and Documents Incorporated By Reference
Filing Submission - Alternative Formats (Word / Rich Text, HTML, Plain Text, SGML, XML, et al.)
Copyright © 2009 Fran Finnegan & Company. All Rights Reserved.
About – Privacy – Redactions – Help —
Sat, 4 Jul 22:27:05.22 GMT 
